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Chapter 1 
Introduction and Outline of the thesis 
 
Regulation of glucose homeostasis 
Glucose is the primary, and in the case of the brain, the essential source of energy for the 
cells in the body. The blood glucose level in the body is tightly regulated and maintained at 
approximately 5 mmol/l. Failure to maintain blood glucose in the normal range leads to 
chronically high (hyperglycemia) or low (hypoglycemia) glucose levels. In the absence of 
adequate treatment, hypoglycemia may result in lethargy, loss of consciousness and, in 
extreme cases, can lead to coma, brain damage and death. In case of persistent 
hyperglycemia, such as untreated diabetes mellitus, the high glucose level in the blood 
represents the main risk factor for development of diabetes-related complications, including 
retinopathy, nephropathy, diabetic neuropathy, and erectile dysfunction (1). 
The blood glucose level is tightly controlled by the reciprocal actions of two 
hormones, insulin and glucagon. The peptide hormone insulin is produced in the pancreas 
in the β-cells of the islets of Langerhans. In response to high blood glucose levels, glucose 
enters the β-cells via the glucose transporter GLUT2. Within the β-cells, glucose is 
metabolized by glycolysis and citric acid cycle and converted into ATP via oxidative 
phosphorylation. The resulting increase in ATP-levels leads to closure of the ATP-
dependent potassium channel at the cell surface and membrane depolarization. Upon 
membrane depolarization, the voltage-dependent calcium channel opens, calcium flows into 
the β-cell and triggers the secretion of insulin directly into the bloodstream. In the body, 
insulin exerts a pleiotropic and anabolic response, the most important effects being the 
suppression of endogenous glucose production by the liver, the stimulation of glucose 
uptake by skeletal muscle and white adipose tissue, the storage of glucose in the form of 
glycogen in liver and skeletal muscle, the stimulation of triglyceride synthesis and 
suppression of lipolysis in white adipose tissue and stimulation of amino acid uptake and 
protein synthesis. Glucagon, which is produced by the α-cells in the islets of Langerhans, 
counteracts the effects of insulin on glucose metabolism by stimulating the release of 
glucose from the liver via stimulation of hepatic gluconeogenesis and glycogenolysis. 
 
Diabetes mellitus 
Diabetes mellitus is a disease characterized by the inability to regulate blood glucose levels, 
resulting in chronically increased blood glucose levels, or ‘hyperglycemia’ (2). Multiple 
types of diabetes mellitus can be distinguished on the basis of the cause of the 
hyperglycemia, which either results from insufficient or even absence of insulin secretion 
by the β-cells, in combination with a suboptimal response of peripheral target tissues to 
insulin, a phenomenon referred to as insulin resistance.  
In case of type 1 diabetes, dysregulation of the immune system results in 
immunological intolerance towards the insulin-producing β-cells. This leads to 
inflammation of the islets of Langerhans and selective destruction of the β-cells (3) Insulin 
synthesis and secretion are also affected in Maturity-onset diabetes of the young (MODY) 
(4) and Maternally inherited Diabetes and Deafness (MIDD), due to genetic factors 




Insulin resistance characterizes type 2 diabetes, the most prevalent type of diabetes, but is 
also found in gestational diabetes and steroid diabetes. In insulin resistance, the production 
of insulin is (initially) normal, but the response induced by insulin in peripheral tissues is 
blunted. When the production of insulin by the pancreas can no longer compensate for the 
peripheral insulin resistance due to β-cell dysfunction, the type 2 diabetes mellitus and 
hyperglycemia become overt. 
 Type 2 diabetes is often found as component of the metabolic syndrome, which is 
characterized by hypertension, central obesity, hyperlipidemia and insulin resistance that 
result in increased mortality due to cardiovascular incidents. The prevalence of both type 2 
diabetes and the metabolic syndrome is reaching epidemic proportions, as the average age 
of onset of both diseases has markedly decreased over the past decades. In order to improve 
insulin action in patients with type 2 diabetes, a detailed understanding of the molecular 
mechanisms of insulin action and how this process is dysregulated under conditions of 
insulin resistance is required. 
 
Mechanism of insulin action 
When reaching its target tissues, the extra-cellular insulin signal is relayed via the insulin 
receptor at the cell surface and the associated post-receptor insulin signal transduction 
pathways. Figure 1 summarizes the key events in the transduction of the insulin signal into 
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The insulin receptor (IR) is a heterodimeric transmembrane protein, consisting of two 
extracellular α-chains responsible for insulin binding and two membrane spanning β-chains 
that contain intracellular tyrosine kinase domains. Insulin binds to the two α-chains of the 
IR on the outer surface of the plasma membrane. This interaction leads to a conformational 
change that induces activation of the intracellular kinase domains. These kinase domains 
subsequently trans-phosphorylate a number of tyrosine residues on the opposite β-chain (6). 
A subset of these phosphorylations stabilize the active conformation and further enhance 
the IR tyrosine kinase activity (amino acids (aa) 1146, 1150 and 1151), while other 
phospho-tyrosine (pY) residues (most notably aa 953, 960 and 972), function as docking 
sites for a number of IR substrates (7). Currently, over ten substrates of the IR have been 
identified, including isoforms of Src-homology-2-containing (Shc (8)), Grb2-associated 
binder 1 (Gab1 (9)), Cas-Br-M (murine) ecotropic retroviral transforming sequence 
homologue (Cbl (10)), the adaptor protein APS (11), and six members of the insulin 
receptor substrate (IRS1-6) family ((12-16), reviewed in (17)). The predominant substrates, 
however, are IRS1 and Shc. They define the two major insulin effector pathways: IRS1 and 
its downstream signaling pathway is responsible for most of the metabolic responses of 
insulin (18-20), while Shc regulates mostly non-metabolic processes induced by insulin, 
such as cell growth, survival and cellular differentiation (21). Both pathways will be 
discussed below. 
 
IRS1 mediated signaling 
The activated IR phosphorylates IRS1 on multiple tyrosine residues, which subsequently 
serve as docking sites for proteins containing Src-homology-2 (SH2) domains, the most 
important being the regulatory p85α subunit of class 1A phosphatidylinositol 3-kinase (PI-
3K (18), reviewed in (22)). PI-3K consists of a p110 catalytic subunit and a p85 regulatory 
subunit. The binding of the p85 subunit via its two SH2-domains to pY residues on IRS1 
leads to activation of the catalytic p110 subunit and recruitment of PI-3K to the plasma 
membrane. There, the p110 subunit catalyses the phosphorylation of specific phospholipids, 
phosphoinositides, on the 3-position to produce phosphatidylinositol-3-phosphates (PIP3), 
especially PI(3,4,5)P3. Signaling molecules that contain pleckstrin homology (PH) domains 
bind this type of lipid second messenger. The local insulin-induced increase in PIP3 results 
in the recruitment of the PH-domain containing kinases phosphoinositide-dependent kinase 
1 (PDK1 (23)) and protein kinase B (PKB; also called Akt (24)) to the plasma membrane. 
PDK1 regulates the activity of members of the AGC family of protein kinases, which 
include protein kinase C (PKC), p70 ribosomal S6 kinase (p70S6K), serum glucocorticoid-
induced kinase (SGK) and PKB/Akt, the latter being one of the most important signaling 
intermediates in metabolic insulin signaling. In case of PKB/Akt, binding to PIP3 facilitates 
the PDK1-mediated phosphorylation of Thr308, one of the sites critical for activation of the 
protein kinase (25). PIP3 is also required for phosphorylation of Ser473 on PKB/Akt by the 
mTORC2 complex, consisting of the protein kinase mammalian target of rapamycin 
(mTOR) bound to a regulatory subunit, known as rapamycin-insensitive companion of 
mTOR (rictor (26;27)). 
 PKB/Akt, when phosphorylated on Thr308 and Ser473 is active and directly 
regulates a number of multiple intracellular substrates important for glucose, protein and fat 
metabolism (see Figure 2, reviewed in (28) and (29)). For example, PKB/Akt regulates the 
activity of AS160 involved in translocation of glucose transporters (GLUT4) to the plasma 
membrane. In addition, PKB inhibits the enzyme glycogen synthase kinase 3 (GSK3), 
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thereby alleviating the repression of glycogen synthase (GS) and stimulating glycogen 
synthesis. PKB affects protein synthesis via phosphorylation of tuberous sclerosis complex 
2 (TSC2; reviewed in (30)). This phosphorylation inhibits TSC2 activity. In complex with 
TSC1, TSC2 negatively regulates mTOR. Thus, the inhibition of TSC2 by PKB efficiently 
activates mTOR. As part of a larger protein complex activated mTOR then regulates 
protein synthesis by phosphorylating p70 S6K and eukaryotic translation initiation factor 
4E binding protein-1 (4EBP1). PKB also regulates the expression of gluconeogenic and 
lipogenic enzymes by controlling the activity of several members of the forkhead box 
(FOXO) family of transcription factors (31;32). Hepatic gluconeogenesis is regulated via 
forkhead box other-1 (FOXO1), which activates gluconeogenic genes. FOXO1 is 
phosphorylated by PKB/Akt and subsequently exported from the nucleus, whereby 
transcription of gluconeogenic genes is terminated (33). The same principle applies to 
another forkhead box transcription factor, FOXA2, which is a crucial regulator of fasting 
lipid metabolism. PKB-mediated phosphorylation of FOXA2 prevents its nuclear 
localization and transcriptional activity (34). 
 
 
Figure 2. The IRS-dependent insulin signaling pathway.  For a detailed description see text. 
 
Shc-mediated signaling 
The other major IR-pathway signals via Shc ((17); Figure 3). The activated IR 
phosphorylates Shc on tyrosines, which facilitates the binding of the adaptor protein growth 
factor receptor bound 2 (Grb2) via its SH2-domain. Via its SH3 domain, Grb2 is bound to 
the nucleotide exchange factor mammalian son-of sevenless (mSos). The recruitment of 
Grb-2-mSos to receptor-associated Shc brings mSos in the vicinity of the small GTP-
binding protein Ras that is localized at the plasma membrane. mSos activates Ras by 
exchanging Ras-bound GDP for GTP. Ras then functions as a molecular switch triggering 
activation of multiple effectors, including PI-3K, Raf and RalGDS. 
 The p110 subunit of PI-3K has been shown to interact with active Ras (35) and 
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normal untransformed Ras, the contribution of mitogen-induced Ras-dependent PI-3K 
activity to the total PI-3K activity is only minor (24;37). Raf-activation is complex (for a 
detailed review see (38)), but Ras-dependent recruitment of Raf to the plasma-membrane 
seems sufficient for its activation. The active Raf kinase then triggers a kinase cascade that 
results in the phosphorylation and activation of MAPK and ERK kinase (MEK1/2). 
Subsequently, MEK1/2 activates the mitogen activated protein kinase (MAPK) family 
member extracellular signal regulated kinase (ERK1/2) via phosphorylation. ERK1/2 
targets include p90 ribosomal protein S6 kinase (p90RSK) and transcription factors such as 
c-Myc, TCF and Elk1, thereby promoting gene expression (39;40). It has been shown that 
ERK does not play a role in mediating the acute metabolic effects of insulin (41;42). 
However its role in the regulation of insulin-induced gene expression has not been 
thoroughly investigated. 
 Insulin-induced Ras activation also leads to the activation of Ras-like small 
GTPase Ral via the Ral-guanine exchange factor Ral-GDS. Via still unknown mechanisms, 
presumably involving Src kinase, Ral then induces activation of the stress-activated protein 
kinases (SAPKs) p38 and JNK (43;44). Targets of these kinases include ATF2 and the 
members of the Jun transcription factor family, in addition to SAP-1, Elk1 and 
MAPKAPK-2 and -3 (40;45;46). The insulin-induced activation of p38 has further been 
described to play a role in insulin-induced glucose transport in a number of differentiated 
cell types (47;48). The role of JNK-activation in insulin-induced responses is still largely 
unknown. 
 
























Previous studies performed in our research group identified ATF2 as a novel component of 
the insulin signaling system in cultured cells (44). The ATF2-phosphorylation in response 
to insulin was found to be dependent on a two-step mechanism which required cooperation 
of the ERK1/2-pathway with one of the SAPK-pathways ((44) and this thesis).  
 The SAPKs p38 and JNK, which are both capable of activating ATF2 on their own 
(e.g. not in cooperation with other kinases) are known to be activated by insulin stimulation 
(47;49). However, increasing evidence suggests that JNK, but also p38, play a key role in 
the development of insulin resistance in a number of tissues (50-53). Therefore, ATF2 can 
function as a potential regulator of insulin-induced gene expression, but can also be 
involved in development of insulin resistance and possible, it can do both. 
 
Outline of this thesis 
The research described in this thesis is aimed at further characterization of the role of ATF2 
in insulin action. Chapter 2 is an introduction to the ATF2 protein, with particular focus on 
its possible functions in metabolic control and insulin action. Chapters 3 and 4 address the 
mechanism of insulin-induced ATF2 phosphorylation in JNK-deficient and JNK-containing 
cultured cells, respectively. In chapter 5, data on the identification of insulin-induced 
ATF2-dependent genes in cultured cells is presented. Chapter 6 describes our findings on 
the in vivo ATF2 regulation by insulin and the effects of high fat diet-induced insulin 
resistance thereon. In chapter 7 these results are summarized and discussed. 
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Activating transcription factor 2 (ATF2) is strongly associated with the cellular 
response to stress stimuli, such as viral infection, pro-inflammatory cytokines, osmotic 
stress and DNA damaging agents. However, ATF2 has also been identified as a 
component of the insulin signaling system, both in vitro and in vivo. Studies in rodents 
and D. melanogaster have implicated ATF2 in the regulation of glucose and lipid 
metabolism via induction of PPARγ coactivator 1α (PGC1α) and 
phosphoenolpyruvate-carboxykinase (PEPCK) expression, suggesting that ATF2 
contributes to metabolic control. Conversely, ATF2 also regulates the expression of 
genes implicated in the development of insulin resistance, β-cell dysfunction and 
complications associated with type 2 diabetes. This suggests that ATF2 not only 
participates in insulin action, but that deregulation of ATF2 activity may contribute to 
the pathogenesis of type 2 diabetes mellitus. This review sheds light on this dual role of 
ATF2 in metabolic control, insulin action and insulin resistance. 
 
The ATF/CREB family of transcription factors. Activating transcription factor 2 (ATF2; 
also referred to as cAMP-Responsive Element (CRE) Binding Protein 2 (CREB2) or CRE-
Binding Protein-1 (CREBP-1)) is part of the mammalian ATF/CREB family of 
transcription factors ((1;2) and Figure 1). All members of the ATF/CREB family share the 
ability to bind to the ATF/CRE consensus site 5’-TG/TACNTCA-3’ and contain a basic 
leucine zipper (bZIP) domain, which is responsible for DNA-binding and dimerization 
(1;2). Whereas the CREB-subfamily members ATF1, CREM and CREB respond primarily 
to cAMP/PKA activation, most of the other members of the ATF/CREB family are 
associated with cellular stress-responses. For example, ATF2-transactivation and ATF3-
expression are predominantly induced by stress stimuli (3;4), whereas ATF4 and ATF6 are 
critical elements of the unfolded protein response induced by endoplasmic reticulum (ER) 
stress (5). 
 
Structure of ATF2. The human ATF2 gene is located on chromosome 2q32 and encodes a 
505 amino acid protein (6). Figure 2 shows a schematic representation of the ATF2 protein, 
which consists of an amino-terminal transactivation domain (TAD) and a carboxyterminal 
bZIP-domain, interconnected by a proline-enriched stretch and a histone acetylase (HAT) 
domain (7;8). ATF2 also contains two nuclear localization signals, a nuclear export signal 
and multiple sites that can be modified by phosphorylation, ubiquitination and 
glycosylation (7;8).  
 ATF2 is highly conserved among species. For example, the mouse ATF2 protein 
is highly similar to the human counterpart, in that it lacks the first 18 amino acids and 
differs in only 2 amino acids in the remaining part of the protein. The ATF2 homolog from 
D. melanogaster, dATF2, displays ~50% sequence similarity with mammalian ATF2 and 







Figure 1. The ATF/CREB family of transcription factors. The protein members can be divided into six 
subgroups, according to their sequence similarity. The box indicates the bZIP  domain. Adapted from (7). 
 
The transactivation domain. Deletion studies using fusion proteins of the DNA-binding 
domain of the yeast transcription factor GAL4 and ATF2 have delineated the minimal TAD 
to amino acids 19-96 ((3), see Figure 2). Structural analysis of amino acids 1-105 divides 
the ATF2-TAD into two subdomains (10). The aminoterminal subdomain (Met19-Gly56) 
contains a Zn-finger motif with a structure very similar to the Zn-fingers found in the DNA-
binding domains of many transcription factors. In contrast to the amino acids responsible 
for interaction with the phosphate backbone of DNA, the two Cys- (Cys27 and Cys32) and 
two His-residues (His45 and His49) that coordinate the binding of the Zn-ion, as well as the 
amino acids that form the hydrophobic core, are well conserved between ATF2 and Zn-
finger motifs of other transcription factors. Although point-mutations of the crucial Zn-
binding residues or complete deletion of the Zn-finger decreased both basal and serum-
induced transcriptional activity of GAL4-ATF2 (11;12), some transcriptionally active 
mammalian isoforms (see Figure 3 and below) and dATF2 lack the Zn-finger motif (9;13-
15). Therefore, the role of the Zn-finger domain in the regulation of ATF2 transactivation 
in vivo remains to be established. 
The structure of the carboxyterminal TAD subdomain (Pro57-Lys105) is highly flexible 
(10). Phosphorylation of several residues within this region, most notably Thr69 and Thr71 
(Figure 2), increases the transcriptional activity of ATF2 (3;16-21), suggesting that this 
subdomain is likely to undergo conformational changes in response to stimuli that promote 
ATF2 activation. Furthermore, the carboxyterminal part of the TAD, including the 














































































Figure 2. Structure of the human ATF2 protein and its subdomains. ATF2 consists of an amino-terminal 
transactivation domain (TAD) and a carboxyterminal bZIP-domain, interconnected by a proline-enriched stretch 
and a histone acetylase domain (HAT). ATF2 also contains two nuclear localization signals, a nuclear export 
signal and multiple sites that can be modified by phosphorylation and glycosylation. The arrows indicate the 
residues critical for zinc binding or residues that can be phosphorylated by protein kinase A (PKA), protein kinase 
C (PKC), extracellular signal regulated kinase (ERK), cJun N-terminal kinase (JNK), p38, or vaccinia-related 
kinase (VRK).  
 
The histone acetylase domain. ATF2 has been found to acetylate histones H2B and H4 in 
vitro (22). The putative HAT domain of ATF2 is located between amino acids 289-311 
(22). Ectopic expression of mutant ATF2 proteins, in which the amino acids critical for in 
vitro HAT activity were replaced by alanines, destroyed the ultraviolet (UV) irradiation-
induced activation of a CRE-dependent luciferase reporter gene (22;23). A role for the 
HAT region in in vivo ATF2 function, however, has not yet been demonstrated. It should be 
noted in this respect that the HAT domain is not conserved in the highly-related ATFa 
protein (also known as ATF7), which can partially compensate for the loss of ATF2 in 
ATF2-/- mice (24). 
The bZIP domain. The bZIP domain is located between Pro351 and Asp417 (Figure 2). The 
basic region (Pro351-Lys382) and leucine zipper (Lys383-Asp417) in the bZIP-domain 
direct DNA-binding and dimer formation, respectively (1;2). Overlapping with the bZIP 
domain, two nuclear localization signals (Arg342-Lys357 and Arg356-Gln371) and a 
leucine-rich nuclear export signal (Val405-Ala414) have been identified (25). 
Based on sequence similarities, the bZIP proteins identified in the human genome 
have been arranged in 12 families, that form 3 subgroups on the basis of their dimerization 
properties (26). Within this classification, ATF2 forms a small family with ATFa and CRE-
BPa. The ATF2-family belongs to the subgroup of bZIP transcription factors that can form 
both homo- and heterodimers (26). ATF2 itself can form heterodimers with several 
members of the CREB/ATF and Jun/Fos families, such as ATF3, cJun and JunD (7). 
Furthermore, several other types of transcription factors, including C/EBP and Smad-
proteins have been found to bind to DNA in association with ATF2 (27-29).   
In ‘in gel-retardation’ assays, the various ATF2-containing dimers all bind the ATF/CRE 
consensus site:  5’-TG/TACNTCA-3’ (13;30;31),  but cause a different degree of DNA  
N C
5051    19                              96                         289   311         351    383       417
TAD HAT bZIPproline-enriched stretch
human ATF2
MSDDKPFLCTAPGCGQRFTNEDHLAVHKHKHEMTLKFG   PARNDSVIVADQTPTPTRFLKNCEEVGLFNELASPFENEFKKASEDDIKK 





















TQNTSGRRRRAANED PDEKRRKFLERNRAAASRCRQKRKVWVQSLEK  KAEDLSSLNGQLQSEVTLLRNEVAQLKQLLLAHKD 











bending, which may contribute to regulatory specificity (32). Compared to the ATF2/ATF2 
homodimer, the ATF2/cJun dimer combination is reported to be a more potent 
transcriptional activator on minimal promoters (13;30;31). However, the relative activities 
of the various dimers on more complex promoters, such as the c-jun promoter (33) or the 
proximal element of the interferon γ (IFNγ) promoter (34) is less clear.  
Isoforms. In all mammalian species examined, distinct ATF2 isoforms exist due to 
differential splicing or alternate promoter usage of the ATF2 gene (9;13-15;35;36). As 
shown for the human and mouse variants in Figure 3, most isoforms contain the bZIP 
domain, but differ in the length of the TAD, the presence of the Zn-finger and the presence 
of the proline-enriched stretch linking the TAD- and HAT-domain (13-15;35). Only one 
described variant of ATF2, termed ATF2sm, lacks most of the bZIP domain. It contains the 
first part of the aminoterminal TAD, including the regulatory residues Thr69 and Thr71 and 
the complete carboxyterminus from the last portion of the bZIP domain (36). Currently, 
only a few isoforms have been analyzed for biological activity (13-15;35;36). However, the 
presence of the bZIP domain in almost all variants suggests normal dimerization and DNA-
binding properties. 
Post-translational modification. ATF2 contains multiple sites that can be modified by 
posttranslational modification, including phosphorylation, ubiquitination and glycosylation. 
Table 1 lists the various phosphorylation sites in ATF2 as well the kinases responsible for 
inducing phosphorylation on these sites. 
 
Table 1. Modification of ATF2 by phosphorylation 
Residue Function Kinase Reference 






















Ser90 unknown JNK (3;19;20) 
Ser121 transactivation Protein kinase Cα (40) 
Ser340 unknown Protein kinase C (37) 
Ser367 unknown Protein kinase C (2) 
Ser490 DNA damage ATM (41) 
Ser498 DNA damage ATM (41) 
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Figure 3. ATF2 isoforms. Alignment of the ATF2 variants in the human (A) and mouse (B) genome. 
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A. Human ATF2 isoforms





As will be discussed in more detail under “Regulation of ATF2 activity”, phosphorylation 
of Thr69 and Thr71 by mitogen-activated protein kinases (MAPK) (see Figure 4 (3;16-21)) 
or Ca2+/calmodulin-dependent kinase IV (CaMKIV (39)) and phosphorylation of Ser62 
and Thr73 by vaccinia-related kinase 1 (VRK1 (38)) enhances the transcriptional activity of 
ATF2. Ser490 and Ser498 are phosphorylated by ataxia telangiectasia mutated (ATM) 
kinase (41). However, these phosphorylations do not affect ATF2 transcriptional activity, 
but link ATF2 to the DNA damage response. The function of Ser90, Ser121, Ser340 and 
Ser367 phosphorylation is less well defined (Table 1). 
 In addition to phosphorylation, ATF2 might also be regulated by glycosylation. 
ATF2 was among the proteins identified in a high-throughput analysis of O-linked β-N-
acetylglucosamine glycosylated proteins from the brain (42). The region of ATF2-
glycosylation (Ala280-Lys296) overlaps in part with the HAT domain, but it remains to be 
determined whether glycosylation affects ATF2 function. Finally, ubiquitination of ATF2 
targets the protein for degradation (43). 
 
Regulation of ATF2 activity. The transcriptional activation capacity of ATF2 is promoted 
by a large number of distinct stimuli associated with cellular stress, such as viral protein 
products, oncogenes, pro-inflammatory cytokines, amino acid starvation, heat shock, 
osmotic stress and DNA damaging agents (3;44), but also mitogenic stimulation with 
epidermal growth factor (EGF), insulin or serum induces ATF2 transactivation (18;45).  
Regulation of ATF2 activity by phosphorylation. The predominant mechanism causing 
ATF2 transactivation involves the phosphorylation of Thr69 and Thr71 (3;19), but  
phosphorylation of other residues may also result in activation of ATF2 (Table 1). The 
MAPK members cJun N-terminal kinase (JNK) or p38 are responsible for the cellular 
stress-induced phosphorylation of both Thr69 and Thr71 (3;16;17;19;20;46). In response to 
growth factors, ATF2-Thr69 and Thr71-phosphorylation is induced via a two-step 
mechanism that requires cooperation of two Ras-dependent MAPK-pathways (18). The 
ERK1/2-pathway induces phosphorylation of Thr71, whereas subsequent Thr69 
phosphorylation is mediated by either p38 or JNK, in a cell type-dependent manner 
((18;45) see Figure 4). ATF2 knock-in mice that express an ATF2 mutant in which Thr69 
and Thr71 were replaced by alanines (ATF2AA), have a phenotype strikingly similar to that 
of the complete ATF2 knock-out mouse (24;47). Also, in D. melanogaster, the p38-
mediated phosphorylation of Thr59 and Thr61, the equivalents of mammalian Thr69 and 
Thr71, was found to be required for transcriptional activation of dATF2 (9;48). These 
studies highlight the importance of Thr69 and Thr71 for ATF2 function. 
 




Figure 4. Regulation of ATF2 activation by insulin and MAPkinases. Activation of the 
Ras−Raf−MEK−ERK1/2 pathway by insulin induces phosphorylation of  Thr71, whereas subsequent Thr69 
phosphorylation requires the Ral−RalGDS−Src−p38 pathway (18;45). 
 
How phosphorylation of the TAD leads to initiation of ATF2-dependent transcription is 
still unclear. Reporter-assays with GAL4-ATF2 fusion proteins have suggested that ATF2 
is held in an inactive conformation by a direct interaction of the Zn-finger in the TAD with 
the bZIP domain (49;50). Consequently, transactivation of ATF2 in response to 
extracellular stimuli has been proposed to involve disruption of this inhibitory interaction 
through phosphorylation or by association with viral or cellular proteins (44;49). Also other 
mechanisms have been suggested via which phosphorylation of Thr69 and Thr71 leads to 
initiation of ATF2-dependent transcription. For example, in response to amino acid 
starvation ATF2-Thr69+71-phosphorylation has been found to precede in vivo acetylation 
of histone H2B and H4 (51). Histone acetylation is thought to facilitate transcription by 
altering the accessibility of DNA to transcriptional activators or chromatin remodelling 
enzymes (52). Future studies should clarify whether the acetylation of H2B and H4 can be 
ascribed to the putative intrinsic HAT activity of ATF2 (22) or results from ATF2-
dependent recruitment of histone acetyltransferases, such as p300/CBP (40;53). Finally, 
phosphorylation of Thr69 and Thr71 has been implicated in ATF2-dimerization and has 
been reported to prevent, but also to promote ubiquitin-dependent degradation of ATF2 in 
different experimental systems (43;54;55). 
Regulation of ATF2 activity by protein-protein interactions. Association of ATF2 with 
transcriptional co-activators or repressors may also affect the transcriptional activity. 
Proteins that activate ATF2 via protein-protein interactions include, in addition to the 
p300/CBP-protein mentioned previously (40;53), the adenoviral E1A protein (12;56), the 

























the co-activator undifferentiated embryonic cell transcription factor 1 (59). In contrast, 
ATF2-dependent recruitment of the repressive histone-variant macroH2A has been reported 
to prevent transcriptional activation of the IL8 gene in a cell-specific manner (60). In 
addition, ATF2-interaction with TBP-interacting protein 49b (61), Jun dimerization protein 
2 (62) and interferon regulatory factor-2-binding protein-1 (63) have been found to 
suppress ATF2 transcriptional activity. 
Subcellular localization. One report suggests that the nuclear transport signals in ATF2 
direct the trafficking of the protein between the nucleus and the cytosol. In certain cell 
lines, heterodimerization with cJun serves to sequester ATF2 in the nucleus (25). Also, 
although ATF2 itself is not sumoylated, sumoylation of ATF2 dimer partners may have an 
impact on ATF2 subcellular localization. Sumoylated cJun and ATFa are transcriptionally 
inactive and at least sumoylated ATFa is primarily localized in the cytosol (64;65). Studies 
in other cell types, however, do not confirm a cytoplasmic localization of ATF2 (45). 
 
 
ATF2-dependent gene expression. The various stimuli and protein-protein interactions 
regulating ATF2-activity as well as the multiple DNA sequences that can bind the different 
ATF2-containing dimers provide numerous levels on which ATF2-dependent target gene 
transcription can be regulated. Accordingly, studies aimed at characterizing ATF2-
regulated genes using knock-out mouse models, gel-retardation assays, as well as ‘ChIP-on-
chip’ analysis using (phosphospecific) ATF2 antibodies in cisplatin-treated cells, have 
generated an enormous list of potential target genes (7;8;24;44;66;67). It should, however, 
be noted that ATF2-dependence has not been validated for all of the identified genes. 
Previous reports addressing the function of ATF2 in oncogenesis and DNA repair (7;8;44) 
have divided the (potential) ATF2 target genes into functional groups, including (i) 
transcription factors (ATF3, c-jun, CHOP, CREB1, Egr1, fosB, FOXO3a, HIF1α, PPARα, 
SREBP1c and TCF7L2), (ii) cell cycle intermediates (CDKN1B, CDKN2A cyclin A and 
cyclin D1), (iii) chemokines and pro-inflammatory cytokines (FasL, IFNβ, IFNγ, IGF2, 
IGFBP6, IL1β, IL4, IL6, IL8, MT3, TGFβ and TNFα), (iv) signaling proteins (AKT1, APS, 
MAP4K4, MKP1, PTEN and SHC1),  (v)proteins engaged in the response to cellular stress 
(ATF3, CHOP and Grp78/BiP) and (vi) proteins involved in the DNA damage response 
(ERCC1, ERCC3, XPA, ATM, RAD23B, FOXD1 and GADD45), (vii) regulators of 
apoptosis (Bcl2, TBcl2-like 11 and TRAF3), (viii) adhesion (E-selectin, P-selectin, VCAM-
1 and collagen), (ix) invasion (MMP2, uPA and iNOS) and (x) metabolism (apolipoproteins 
A1 and C3, insulin, PEPCK and PCG1α)(24;34;39;48;66-93). 
As shown in Table 2, a large number of these (potential) ATF2 target genes also 
play regulatory roles in insulin action, β-cell (dys)function and/or glucose- and lipid 
metabolism. Other potential ATF2-regulated genes have been linked to the pathogenesis of 
type 2 diabetes (T2D) and diabetes-related complications. Intriguingly, phosphorylation of 
ATF2 is not only increased by insulin in vitro and in vivo, but also in rodent models of 
high-fat diet induced insulin resistance. Below, we will discuss the possible functions of 
ATF2 in relation to normal metabolic control and the pathogenesis of T2D. 
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Table 2. Functional classification of (potential) ATF2-target genes involved in insulin 
action, β-cell function and type 2 diabetes 
Function Genes References 
Adipocyte dysfunction HIF1α, IGF2, IL1β, IL6, MMP2, MT3, 
TNFα 
(66;67;83;84) 
Candidate genes for T2D CDKN2A, MAP4K4, TCF7L2 (66;88) 
ER stress ATF3, CHOP, Grp78/BiP (68;71;78) 
Glucose metabolism PEPCK, PCG1α, SREBP1c (48;69;70;72;73) 
Inhibition of insulin 
signaling 
IL1β, IL6, PTEN, TNFα  (67;83;84;92;93) 
Insulin signaling AKT1, APS, FOXO3a, MKP1, SHC1 (24;66) 





collagen, Egr1, E-selectin, HIF1α, iNOS, 
P-selectin, TGFβ, VCAM-1 
(66;67;77;80;81) 
β-cell (dys)function ATF3, IL1β, insulin (39;67;68;90) 
 
ATF2 and metabolic regulation.  
Lessons from animal models. Various mouse models with deletions in the ATF2 gene have 
been generated. The first mouse described, ATF2m/m, expresses low levels of an ATF2-
variant lacking amino acids 277-329 (47;94). These mice were born, displayed lower 
viability and growth in addition to bone abnormalities and reduced numbers of Purkinje 
cells in the brain (94). Mice completely lacking ATF2 die shortly after birth due to 
respiratory problems (47), while knock-out mice lacking both ATF2 and its closest 
homologue ATFa (also known as ATF7), or mice expressing ATF2 mutated at Thr69 and 
Thr71 on an ATFa-/- background, are not born due to developmental abnormalities in heart 
and liver, both in hepatocytes and the hematopoietic cells, already apparent at E12.5 (24). 
Unfortunately, experiments performed with these mouse models do not provide information 
on the role of ATF2 in metabolic control.  
 Selective ablation of dATF2 in the fat body of D. melanogaster, however, does 
identify a metabolic function for dATF2 (48). The fat body serves to sense energy and 
nutrient availability and coordinates the appropriate metabolic response. Knockdown of 
dATF2 in the fat body severely reduced phosphoenolpyruvate carboxykinase (PEPCK) 
expression. PEPCK is a crucial enzyme in hepatic glucose production and in lipid 
homeostasis in adipose tissue (95;96). In the D. melanogaster fat body, the ATF2/PEPCK 
pathway was found to regulate lipid metabolism and more specifically the synthesis of 
triglycerides from glycerol-3-phosphate (48).  
Lessons from in vivo and in vitro studies. Studies in rat hepatoma cells have confirmed the 
regulation of PEPCK expression through the p38/ATF2 pathway in response to arsenite and 
retinoic acid (72;73). Furthermore, the ATF2 target gene and potential dimer-partner ATF3 
has been linked to suppression of PEPCK expression in vivo (97). Insulin is known to 
decrease PEPCK levels in the liver (95), but an involvement of the ATF2/ATF3 pathway in 
this process remains to be determined. ATF2 has further been implicated in the regulation 
of PPARγ co-activator 1α (PGC1α). This transcriptional co-activator is activated by signals 
that control energy and nutrient homeostasis (98;99). In brown adipose tissue and skeletal 
muscle, the p38/ATF2 pathway contributes to PGC1α induction in response to a β-
adrenergic stimulus and exercise, respectively (69;70;100). 
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A gene profiling study on chromatin immunoprecipitated from cisplatin-treated breast 
cancer cells with a phosphospecific ATF2 antibody identified more enzymes involved in 
the regulation of glucose and lipid metabolism, such as sterol regulatory element binding 
protein 1c (SREBP1c), peroxisome proliferator activated receptor α (PPARα) and the 
apolipoproteins A1 and C3, as well as components of the insulin signaling system, 
including Akt1, adaptor protein containing PH and SH2 domains (APS), FOXO3a, Map 
kinase phosphatase 1 (MKP1) and Src homologous collagen-1 (SHC1) (66). Except for 
apolipoprotein C3 and MKP1, a role for ATF2 in the regulation of these genes has not been 
validated yet. Apolipoprotein C3 is a very low density lipoprotein (VLDL) protein and 
inhibits lipoprotein lipase and hepatic lipase, thereby delaying the breakdown of 
triglyceride-rich particles. DNAseI footprinting analysis and gel retardation studies have 
demonstrated ATF2 binding to the apolipoprotein C3 promoter (91). Also, ATF2 stimulates 
apolipoprotein C3 promoter activity in reporter assays in HepG2 cells (91).  
In cultured cell lines, the expression of MKP1 is induced by insulin and blunted by 
shRNA-mediated silencing of ATF2 ((101); BB and DMO, unpublished results: see 
Chapter 5). Also studies in embryonic livers from mice lacking both ATF2 and ATFa (also 
known as ATF7) confirm MKP1 as an ATF2-regulated gene (24). MKP1 is a negative 
regulator of the upstream activators of ATF2, i.e. the MAP kinases p38, JNK and ERK1/2 
(24;102). In adipocytes, MKP1 has an inhibitory effect on the production of monocyte 
chemoattractant protein 1 (MCP1), a chemokine highly associated with the development of 
adipocyte dysfunction in insulin resistance (103). Conversely, mice lacking the MKP1 gene 
are resistant for diet-induced obesity (104). Therefore, further studies are clearly required to 
clarify the role of MKP1 in in vivo insulin action. 
ATF2 has also been implicated in the regulation of β-cell function and 
proliferation. In isolated rat islets, Ca2+-induced activation of CAMKIV leads to 
phosphorylation of ATF2 and induction of ATF2-dependent insulin expression (39). 
Transfection studies in rat insulinomas confirm ATF2 as crucial regulator of glucose-
induced insulin transcription by demonstrating ATF2 binding to a CRE-binding element in 
the human insulin promoter (90). ATF2 further regulates the induction of the cyclin D1 
gene in response to regenerating gene product stimulation of β-cells (105). Finally, gene 
variants in two other cell cycle regulators, i.e. cyclin-dependent kinase inhibitor 2A 
(CDKN2A) and transcription factor 7 like 2 (TCF7L2, also known as TCF4), that associate 
with type 2 diabetes and reduced insulin secretion (106;107), were also identified as 
potential ATF2-regulated genes in a ChIP-on-chip analysis using (phosphospecific) ATF2 
antibodies in cisplatin-treated cells (66).  
 
ATF2 and insulin resistance. Insulin resistance in combination with insufficient 
compensatory insulin secretion due to β-cell dysfunction characterizes type 2 diabetes 
(T2D) (108). One of the features of insulin resistance is elevated activity of the stress 
kinase JNK in several insulin target tissues including liver, fat and adipose tissue 
((109;110) reviewed in (111)). High fat diet (HFD)-induced insulin resistance in rodent 
models is mitigated by pharmacological or shRNA-mediated inhibition of JNK activity 
(112-114). Furthermore, it was found that JNK1-, but not JNK2-knockout mice are resistant 
to the development of insulin resistance induced by HFD (109;115). JNK activation has 
been described to inhibit insulin signaling directly via serine phosphorylation of IRS 
proteins, thereby interfering with tyrosine phosphorylation of the proteins and subsequent 
activation of downstream signaling  pathways  (116).  Alternatively, JNK may affect insulin 
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sensitivity indirectly via expression of pro-inflammatory cytokines (116;117). In the insulin 
resistant state, macrophages infiltrate major insulin target tissues, such as liver and adipose 
tissue, and various cytokines, including IL6 and TNFα, are released by both macrophages 
and adipose tissue (118). In hepatocytes, IL6 has been linked to the induction of suppressor 
of cytokine signaling 3 (SOCS3) (119), a protein that binds to and inhibits the insulin 
receptor, but also targets the IRS proteins for proteasomal degradation (120;121). In 3T3L1 
adipocytes, TNFα increases the expression of MAP4K4 (88). MAP4K4 is an upstream 
activator of JNK (Figure 4), has been identified as T2D candidate gene (122) and is 
reported to inhibit adipocyte differentiation and glucose uptake in adipocytes (123). In 
primary muscle cells isolated from human subjects with T2D, silencing of MAP4K4 
restored insulin sensitivity and prevented TNFα-induced insulin resistance (124).  
ATF2 has been implicated in induction of IL6, TNFα and MAPK4K4. Silencing 
ATF2 in 3T3L1 adipocytes abrogates the induction of MAP4K4 (88) and expression of 
wildtype ATF2 is required for maximal induction of IL6 and TNFα  in mouse models (67). 
Also, studies in D. melanogaster support the role of ATF2 in the immune response (9). 
Interestingly, ATF2-phosphorylation is elevated in both the liver and white adipose tissue 
from HFD-fed mice (125), suggesting that ATF2 may participate in the pathogenesis of 
insulin resistance, in addition to and possibly as a downstream effector of JNK. 
 Furthermore, increased JNK activity was also found in the hypothalamus of HFD-
induced insulin resistant mice (126). As ATF2 is highly expressed in the brain (2), amongst 
others in the arcuate nucleus (127), a region of the hypothalamus that is associated with the 
control of food intake (128;129), this finding potentially links neuronal ATF2 with the 
metabolic disturbances found in the insulin resistant state. 
 An important question is whether activation of the JNK/ATF2-axis within a 
specific organ might be responsible for the development of insulin resistance. In contrast to 
ATF2, mice with tissue-specific alterations in JNK1 activity have been generated and 
analyzed for alterations in insulin sensitivity following high-fat feeding. Whereas 
overexpression or ablation of JNK in skeletal muscle does not affect glycogen metabolism, 
or protein levels of key molecules regulating glucose metabolism (130;131), liver-specific 
knockdown of JNK1 led to a significant reduction in plasma glucose and insulin levels and 
enhanced insulin-mediated phosphorylation of PKB/Akt (132). In line with these data, mice 
with antisense oligonucleotide-mediated JNK1-silencing in liver failed to develop insulin 
resistance and steatohepatitis in response to high-fat feeding (114). Mice with specific 
ablation of JNK1 in adipose tissue show a greatly reduced susceptibility to insulin 
resistance induced by high-fat feeding (119). In addition, the HFD-induced expression and 
secretion of IL6 in adipose tissue was abrogated in adipose-specific JNK1 knock-out mice 
(119). As described above, IL6-induced expression of hepatic SOCS3 may contribute to 
insulin resistance. In support of this model, mice with a fat-specific deletion of JNK1 are 
protected against HFD-induced increase in SOCS3 expression and abrogation of insulin-
mediated PKB/Akt-phosphorylation in the liver (119). As the accumulation of macrophages 
in adipose tissue may also trigger the inflammatory changes seen in insulin resistance and 
T2D, various groups have generated mice with JNK1 deficiency in myeloid and 
hematopoietic cells. One report shows that ablation of JNK1 in myeloid cells ameliorates 
obesity-induced insulin resistance, but subsequent studies did not confirm this finding 
(119;133-135). Interestingly, all reports found a reduction in the expression of the ATF2 
target genes TNFα and IL6 in adipose and hepatic tissue of macrophage-specific JNK-
deficient mice.  
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 Despite these suggestive data, the involvement of ATF2 in JNK-dependent 
processes associated with insulin resistance has not been thoroughly examined. Future 
studies on mice with a tissue-specific ablation of ATF2 are required to detail the 
contribution of ATF2 to these JNK-dependent processes. 
 
ATF2 and β-cell dysfunction. Islet cells from patients with T2D show increased 
inflammation characterized by the presence of immune cell infiltration, amyloid deposits, 
cytokines and apoptotic cells (136). Various studies implicate ATF2 and ATF2-regulated 
genes in β-cell dysfunction and apoptosis. Exposure of β-cells to amylin induces a p38-
dependent increase in ATF2-phosphorylation (137). Furthermore, amylin-induced apoptosis 
is prevented by silencing of ATF2 (137). The increase in ATF2 phosphorylation induced by 
IL1β is mediated by JNK and inhibition of JNK prevents IL1β-induced apoptosis 
(138;139). Future studies should detail whether the induction of ATF2-regulated genes, 
IL1β, ATF3, CHOP and BiP/Grp78 (66;68;71) also contributes to β-cell dysfunction and 
apoptosis. Increased expression of ATF3 in β-cells has been found to lower the levels of 
IRS2, a key regulator of β-cell survival (140). The induction of IL1β by ATF2 may cause a 
vicious cycle resulting in progressive β-cell loss. Furthermore, IL1β exposure of β-cells 
results in endoplasmic reticulum stress, amongst others via the induction of ATF3, CHOP 
and BiP/Grp78 (141). 
  
ATF2 and T2D-associated complications. Endothelial dysfunction is a co-morbidity in 
T2D and insulin resistance. Insulin regulates vasodilation by increasing endothelial nitric-
oxide synthase (eNOS) activity through the PI3K-PKB/Akt-pathway (142). In insulin 
resistance, defects in insulin-induced endothelium-dependent vasodilation have been 
reported (143). ATF2 has been found in complex with the promoter of phosphatase and 
tensin homolog (PTEN).  Furthermore, two potential inducers of endothelial dysfunction in 
T2D, resistin and free fatty acids, have been found to increase PTEN levels in endothelial 
cells via activation of the p38/ATF2-pathway (92;93). PTEN acts as a phosphatase to 
dephosphorylate the product of PI3K, phosphatidylinositol (3,4,5)-triphosphate (PIP3). 
Thus, activation of ATF2 can contribute to endothelial dysfunction by inhibiting the PI3K-
PKB/Akt- dependent phosphorylation of eNOS (142). 
  The characterization of ATF2-target genes in cisplatin-treated breast cancer cells 
also identified several genes (66) including collagen, early growth response 1 (Egr1), E-
selectin, IGF2, inducible nitric oxide synthase (iNOS), P-selectin, transforming growth 
factor β (TGFβ) and vascular cell adhesion molecule 1 (VCAM-1), that are associated with 
endothelial dysfunction as well as other T2D-associated complications, like tissue fibrosis 
and diabetic nephropathy (144-147). However, further clarification of the involvement of 
ATF2 in these processes is still needed. 
 
Conclusions and perspectives. ATF2 has been identified as component of the insulin 
signaling system in vitro and in vivo (18;45;125). The nature of the ATF2-regulated genes 
suggests a function for ATF2 in the regulation of glucose and lipid metabolism, as well as 
β-cell function. Genetic evidence from D. melanogaster supports a function for ATF2 in 
lipid metabolism. Intriguingly, in obesity and insulin resistance, a sustained increase in the 
activity of the p38/ATF2- and JNK/ATF2-signalling pathways is observed, which may 
contribute to the development of T2D and associated complications. Future studies should 
elucidate whether insulin or conditions associated with insulin resistance and obesity induce 
distinct sets of ATF2-target genes.  
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Growth factors activate ATF2 via sequential phosphorylation of Thr69 and Thr71, 
where the ATF2-Thr71-phosphorylation precedes the induction of ATF2-Thr69+71-
phosphorylation. Here, we studied the mechanisms contributing to serum-induced 
two-step ATF2-phosphorylation in JNK1,2-deficient embryonic fibroblasts. Using 
anion exchange chromatography, ERK1/2 and p38 were identified as ATF2–kinases in 
vitro. Inhibitor studies as well as nuclear localization experiments show that the 
sequential nuclear appearance of ERK1/2 and p38 determines the induction of ATF-
Thr71 and ATF2-Thr69+71-phosphorylation in response to serum. 
 
ATF2 is a ubiquitously expressed member of the cAMP-responsive element (CRE)-binding 
protein family of basic region-leucine zipper (bZIP) transcription factors also including 
CREB (1) and ATF3, ATF4, ATF6 and B-ATF (2;3). ATF2 can form homo- and 
heterodimers with other ATF-family members (3), but also with the activating protein-1 
(AP-1) family member cJun (4). The various dimer compositions confer an enormous  
repertoire of target genes on ATF2, which include cell cycle regulators, proteins involved in 
invasion or adhesion, growth factors and pro-inflammatory cytokines, DNA repair genes, 
transcriptional factors and molecules associated with metabolic control (5;6). 
 In the absence of a stimulus, ATF2 is held in an inactive conformation (7). 
Phosphorylation of residues within the activation domain leads to ATF2 transcriptional 
activation (8-10). In particular, phosphorylation of two threonine (Thr) residues, Thr69 and 
Thr71, is required and sufficient for transcriptional activation of ATF2 (11;12).  
 Inducers of cellular stress, like pro-inflammatory cytokines, oncogenes, viruses, 
heat shock, osmotic stress and DNA-damaging agents as well as growth factors, increase 
the transactivation capacity of ATF2 through phosphorylation of the Thr69 and Thr71 
residues. The activation pattern induced by mitogens, however, differs from that mediated 
by inducers of cellular stress. Cellular stresses induce a prolonged phosphorylation of 
ATF2, whereas the activation induced by growth factors is much more transient and, 
importantly, is elicited via a two-step mechanism (13). Within minutes after the addition of 
growth factors, phosphorylation of ATF2-Thr71 is induced, whereas subsequent 
phosphorylation of ATF2-Thr69 occurs several minutes later. Notably, this mechanism 
involves cooperation of distinct Ras-effector pathways. The Ras-Raf-MEK-ERK1/2 
pathway directs the phosphorylation of ATF2-Thr71, whereas the Ras-Ral pathway is 
required for subsequent ATF2-Thr69 phosphorylation. 
 Here, we studied the mechanisms contributing to serum-induced two-step ATF2-
phosphorylation in JNK1,2-deficient embryonic fibroblasts. Therefore, ATF2 kinases were 
purified from serum-treated cells by anion exchange chromatography. Using 
pharmacological inhibitors and nuclear localization experiments, we further detailed the 
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The main ATF2 N-terminal kinase activities co-purify with ERK1/2 and p38 in serum-
treated JNK1,2 -/- cells. To identify ATF2-kinases in JNK1,2-/- cells, cell lysates prepared 
after 10 min of serum stimulation were fractionated by anion-exchange chromatography on 
monoQ columns. Analysis of the obtained fractions showed that the bulk of ATF2-directed 
kinase activity co-purified with fractions containing ERK1/2. A smaller peak of ATF2-
directed kinase activity was recovered in a fraction co-purifying with p38 (Figure 1A, solid 
line). 
 Incubation of the cells with U0126, an inhibitor of the upstream activator of 
ERK1/2: MEK1/2 (14), strongly reduced the serum-induced ATF2 kinase activity in the 
fractions co-purifying with ERK1/2 (Figure 1A, dashed line). Furthermore, addition of the 
p38 inhibitor SB203580 (15) to the in vitro kinase assay  completely blocked ATF2-kinase 
activity in the fraction co-purifying with p38 (Figure 1B). Similar results were obtained for 
JNK1,2-/- cells treated with epidermal growth factor (EGF) (data not shown). Thus, the 
major ATF2-directed kinase activities in growth factor stimulated JNK1,2-/- cells are 
represented by ERK1/2 and p38. 
 
Figure 1. Identification of ERK1/2 and p38 as the major ATF2 kinases activities in JNK -/- cells. (A) JNK-/- 
cells, pretreated with vehicle (solid line) or U0126 (dashed line) for 15 minutes, were FCS stimulated for 10 
minutes before lysis. MonoQ anion exchange-fractionation was performed on these lysates and the obtained 
fractions were used in an ATF2-directed in vitro kinase assay using GST-ATF2 as substrate. ATF2-Thr71 specific 
phosphorylation of GST-ATF2 was determined by Western blotting using the ATF2-Thr71 phospho-specific 
antibody. Relative ATF2-Thr71 reactivity was plotted against MonoQ fraction number. The presence of phospho-
ERK1/2 and p38 MAPK in the different fractions was determined by western blotting. (B) The p38-containing 
MonoQ fraction (#17) was used in an in vitro kinase assay in the presence of vehicle or SB203850 with GST-
ATF2 as the substrate. ATF2-Thr71 specific phosphorylation of GST-ATF2 was determined by Western blotting 
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Inhibition of ERK1/2 and p38 differentially abrogates ATF2-Thr71 and ATF2-Thr69+71 
phosphorylation in serum-stimulated JNK1,2 -/- cells.As both ERK1/2 and p38 were 
identified as ATF2-directed kinases from JNK1,2-/- cells, we next analyzed the effects of 
U0126 and SB203580 on serum-induced ATF2-Thr71 and ATF2-Thr69+71 
phosphorylation. Western blot analysis of lysates of JNK1,2-/- cells, showed that ATF2-
Thr71 phosphorylation was induced after 2-4 min, whereas the onset of ATF2-Thr69+71 
was detected at 4-6 min after serum addition (Figure 2A). 
The presence of SB203580 lowered the absolute levels of Thr71-phosphorylated ATF2 
both in the basal state as well as following incubation with serum (Figure 2B/C). However, 
the fold-induction (as compared to t=0 minutes) of ATF2 Thr71-phosphorylation by serum 
was slightly enhanced in the presence of SB203580 (Figure 2B/C). The complete inhibition 
of the serum-induced phosphorylation of MAPKAPK-2 (16), another downstream target of 
p38, confirmed effectiveness of SB203580 (Figure 2D). In contrast to SB203580, the 
presence of U0126 completely abrogated the induction of ATF2-Thr71 phosphorylation by 
serum (Figure 2B). These results suggest that, in these cells, ERK1/2 rather than p38 is 
responsible for the phosphorylation of ATF2 on Thr71 observed at 2-4 minutes after serum 
stimulation. In line with previous reports showing that ERK1/2 is not capable of 
phosphorylating ATF2 on Thr69 (13;17), the presence of SB203580, but not U0126, 





Figure 2. Inhibition of ERK1/2 and p38 differentially abrogates ATF2-Thr71 and ATF2-Thr69+71 
phosphorylation in serum-stimulated JNK1,2 -/- cells. (A) Serum-starved JNK-/- cells were treated with 20% 
fetal calf serum (FCS). Total cell lysates were prepared at indicated time-points and analyzed by Western blotting 
using phospho-specific ATF2-Thr71 and ATF2-Thr69+71 antibodies. (B) Serum-starved JNK  -/- cells were pre-
incubated for 30 minutes with vehicle or inhibitors U0126  or SB203580 before serum-stimulation (FCS; 20%) for 
the times indicated. ATF2-Thr71- and Thr69+71-phosphorylation levels were determined by immunoblotting with 
specific antibodies. (C) The relative ATF2-Thr71 phosphorylation of the vehicle and SB203580-treated lysates 
were quantified and plotted against the time of stimulation. (D) Serum-starved JNK-/- cells were treated with 
carrier or SB, FCS-stimulated for 10 minutes and lysed as described above. MAPKAPK-2 phosphorylation was 










































The onset of ATF2-Thr71 and ATF2-Thr69+71-phosphorylation associates with nuclear 
translocation of ERK1/2 and p38. Immunofluorescence experiments showed that 
phosphorylated ATF2 is localized in the nucleus and confirmed that the p38 inhibitor 
SB203580 abolished serum-induced phosphorylation of ATF2-Thr69+71, but not of ATF2-
Thr71 (Figure 3).  
 
 
Figure 3. Serum-induced ATF2-Thr69+71, but not Thr71-phosphorylation is SB203580-sensitive in JNK-/- 
cells. Serum-starved JNK-/- cells were treated with SB203580 (SB) for 30 minutes prior to stimulation with 20% 
serum (FCS) for 8 minutes. Cells were fixed and stained with antibodies for (A) Thr71- or (B) Thr69+71-
phosphorylated ATF2 followed by FITC-conjugated secondary antibodies (green). DNA was stained with DAPI 






















Serum stimulation of JNK1,2-/- cells induced the phosphorylation of both ERK1/2 and p38 
within 2 minutes (Figure 4A). As the MAPkinases involved in ATF2-phosphorylation are 
simultaneously activated, their sequential role in ATF2-phosphorylation cannot simply be 
explained by sequential activation. Therefore, we determined if differences in nuclear 
appearance of ERK1/2 and p38 might determine the differential onset of ATF2-Thr71 and 
ATF2-Thr69+71 phosphorylation. 
Using cell fractionation and immunofluorescence procedures, we found that within 
2 minutes, serum induced the nuclear translocation of phosphorylated ERK1/2 (Figure 
4B/5A) and that this was paralleled by the induction of ATF2-Thr71 phosphorylation 
(Figure 4B). Nuclear translocation of phosphorylated p38 was observed 4 minutes after 
serum addition and was paralleled by ATF2-Thr69+71 phosphorylation (Figure 4B/5A).  
Purity of the cell fractions was checked by Western Blotting, using EF-1β and 






Figure 4. The onset of ATF2-Thr71 and ATF2-Thr69+71-phosphorylation coincides with the appearance of 
ERK1/2 and p38 in nuclear fractions (A) Lysates from serum-starved JNK-/- cells prepared at the indicated time 
points after FCS stimulation were examined for phosphorylation of ERK1/2 and p38 and ATF2-Thr71 and 
Thr69+71 by immunoblotting with phospho-specific antibodies as described. (B) Serum-starved JNK-/- cells were 
serum-stimulated as described, at the times indicated cellular fractions were prepared and the nuclear fractions 
examined for phosphorylation of ERK1/2 and p38 and ATF2-Thr71 and Thr69+71 by immunoblotting with 
phospho-specific antibodies as described. (C) Serum-starved JNK-/- cells were serum-stimulated as described, at 
the times indicated cellular fractions were prepared and the purity of both cytosolic (CF) and nuclear (NF) 
























Finally, the presence of SB203580 abrogated nuclear phospho-p38 immunoreactivity found 
in response to serum (Figure 5B) and severely reduced the serum-induced phospho-ATF2-





Figure 5. The onset of ATF2-Thr71 and ATF2-Thr69+71-phosphorylation associates with nuclear translocation of 
ERK1/2 and p38. (A) Serum-starved JNK-/- cells were stimulated with 20% serum (FCS) and fixed at the times 
indicated. The fixed cells were stained with antibodies for phospho-ERK1/2 (ERK1/2-PP) or phospho-p38 (p38-
PP) followed by FITC-conjugated secondary antibodies (green). DNA was stained with DAPI (blue). (B) Serum-
starved JNK-/- cells pre-treated with vehicle or SB203850 for 30 minutes prior to 8 minute FCS-stimulation were 
fixed and stained for phospho-p38 (p38-PP) as described above. (C) Serum-starved JNK-/- cells, pre-treated with 
vehicle or SB203850 were serum-stimulated for 8 minutes, after which cellular fractions were prepared and the 
nuclear fractions examined for p38- and ATF2-Thr69+71 phosphorylation by immunoblotting with phospho-
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Discussion 
The present study identifies the MAP kinases ERK1/2 and p38 as the major growth factor-
induced ATF2-directed kinases in JNK-/- cells and elucidates their role in two-step ATF2-
phosphorylation mechanism in response to growth factors. 
Using MonoQ anion exchange chromatography we found that, in JNK-/- cells, the 
major serum-induced ATF2-directed kinase activities co-purified with the ERK1/2 and p38 
fractions (Figure 1A). MonoQ separation of EGF- or insulin-stimulated JNK-deficient cell 
lysates resulted in similar ATF2-kinase profiles (data not shown), suggesting that these 
kinases are involved in general mitogenic signaling towards ATF2. 
The role of ERK1/2 and p38 in serum-stimulated ATF2 phosphorylation in JNK-
deficient fibroblasts was further established by inhibitor studies: treatment of these cells 
with U0126 abolished the serum-induced ATF2-kinase activity in the ERK1/2-containing 
fraction and reduced the early ATF2 phosphorylation on Thr71 found in cell lysates (Figure 
1 and 2) This suggests that ERK is the kinase responsible for the first phosphorylation of 
ATF2 on Thr71 in response to serum. 
As ERK1/2 is incapable of phosphorylating ATF2 on Thr69 (13;17), cooperation 
with another kinase seems necessary for efficient ATF2-Thr69+71 phosphorylation. Our 
study identified p38 as the other ATF2-directed kinase in serum-treated JNK-/- cells. p38 is 
known to be capable of phosphorylating ATF2 on both Thr69 and 71 residues (13;17;18). 
In response to inducers of cellular stress the onset of ATF2-Thr69+71 coincides with the 
onset of ATF2-Thr71-phosphorylation and this process seems completely p38-dependent in 
JNK-deficient cells (13;17). This raises the question whether activation of p38 alone may 
be sufficient for the induction of ATF2-phosphorylation in response to serum. Our data 
suggest that ERK1/2 activation is biologically relevant for serum-induced two-step ATF2-
phosphorylation. In contrast to ERK1/2, the activity of p38 is low in serum-stimulated 
fibroblasts and, therefore, insufficient to phosphorylate ATF2 Thr71 and/or Thr69 
efficiently by itself. However, these low levels of active p38 are essential and appear to be 
sufficient to phosphorylate Thr69 when ATF2 is already mono-phosphorylated on Thr71 by 
ERK1/2. Furthermore, recombinant p38 was reported to phosphorylate GST-ATF2 via a 
double collision mechanism in vitro (19). After the first (random) phosphorylation event of 
ATF2 on Thr69 or Thr71, p38 dissociates from the mono-phosphorylated ATF2 substrate. 
It then re-associates with ATF2 for phosphorylation of the second threonine. Importantly, 
the efficiency of the second phosphorylation step is differentially affected by the two mono-
phosphorylated forms of ATF2: whereas Thr71-phosphorylated ATF2 was readily 
phosphorylated on Thr69, ATF2 mono-phosphorylated on Thr69 was found to be an 
inefficient substrate for p38-mediated Thr71- phosphorylation. Thus, efficient 
phosphorylation of ATF2 by recombinant active p38 only occurs in the order Thr71  
Thr69+71. In our JNK-deficient system, phosphorylation of ATF2-Thr71 by ERK1/2 might 
prime ATF2 for subsequent efficient ATF2-Thr69-phosphorylation by p38. Accordingly, 
inhibiting p38 activity reduced the ATF2-directed activity present in p38-containing 
MonoQ fraction and abolished the serum-induced ATF2-Thr69 phosphorylation found in 
JNK-/- cell lysates (Figure 1, 2 and 3). These findings suggest that in these cells, ERK1/2 
and p38 cooperate to efficiently phosphorylate ATF2 on Thr69 and Thr71. 
Finally, localization studies using cell fractioning and immunofluorescence 
experiments showed that although ERK1/2 and p38 are activated simultaneously in 
response to serum in JNK-/- cells, the nuclear appearance of these kinases is different, with 
nuclear presence of ERK1/2 preceding p38. Notably, the nuclear appearance of ERK1/2 
correlated with the ATF2-Thr71 phosphorylation, while nuclear translocation of p38 
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paralleled the detection of phospho-Thr69+71 ATF2. In addition, treatment of JNK-/- cells 
with SB203580, which abolished ATF2-Thr69+71 phosphorylation, also prevented nuclear 
appearance of phosphorylated p38.  These results suggest that despite simultaneous 
activation of ERK1/2 and p38 by serum, their differential nuclear appearances can explain 
the differential kinetics of ATF2 phosphorylation. 
The data presented in this study suggest that the serum-induced two-step 
mechanism of ATF2-phosphorylation in JNK-deficient cells is dependent on cooperation of 
ERK1/2 with p38. We propose that sequential nuclear appearance of these kinases is a 
determining factor driving this mechanism. 
 
Materials and Methods 
Cell culture and cell stimulation. JNK8 cells (JNK1 and 2 knockout embryonic fibroblasts) 
were cultured in Dulbecco’s modified Eagle’s medium (DMEM) containing 9% fetal 
bovine serum (FBS) and antibiotics. Before cell-stimulations, the cells were serum-starved 
(DMEM w/ 0.5% FBS) for 16h. When inhibitors were used, cells were pre-treated for 30 
minutes with 2.5 µM SB203580 (Promega) or for 15 minutes with 10 µM U0126 
(Promega), before addition of serum (FCS) to 20%. 
Western blot analysis and antibodies. Whole cell lysates were prepared from 9 cm dishes 
that were rinsed twice with ice-cold phosphate-buffered saline (PBS) and lysed in 750 µl 
Laemmli sample buffer. Proteins were separated on polyacrylamide slab gels and 
transferred to Immobilon (Millipore). Blots were stained with Ponceau S before blocking to 
verify equal loading and appropriate protein transfer. Filters were incubated with antibodies 
as described previously (13). The antibodies used were: Lamin A and phospho-specific 
ATF2-Thr69+71, ATF2-Thr71, p38-Thr180/Tyr182, ERK1/2-Thr202/Tyr204 and 
MAPKAPK2-P (all polyclonal, Cell Signaling); p38 (N-20), ATF2 (C-19) and ERK1/21 
(K-23) (Santa Cruz) and secondary antibodies: goat anti-rabbit and goat anti-mouse IgG–
HRP conjugate (Promega). The Elongation Factor (EF)-1β antibody was described 
previously (20). The specificity of the phospho-specific ATF2 antibodies (P71 and P69+71) 
has been verified previously (13;17). 
MonoQ/anion-exchange chromatography. Anion-exchange chromatography was performed 
essentially as described previously (13). Briefly, stimulated cells were scraped in MonoQ 
lysis buffer [20 mM Tris (pH 7.0), 0.27 M sucrose, 1 mM EDTA, 1 mM EGTA, 1% Triton 
X-100, 10 mM sodium β-glycerolphosphate, 50 mM NaF, 5 mM sodium pyrophosphate, 1 
mM sodium orthovanadate, 0.1% (v/v) β-mercaptoethanol and Complete protease inhibitors 
(Roche Biochemicals)]. Lysates of six 9-cm dishes (~8000 mg protein) were diluted 
twofold with MonoQ buffer [50 mM Tris.Cl (pH 7.5), 1 mM EDTA, 1 mM EGTA, 5% 
(v/v) glycerol, 0.03% (w/v) Brij-35, 1 mM benzamidine, 0.3 mM sodium orthovanadate and 
0.1% (v/v) β-mercaptoethanol] and applied to a MonoQ HR 5/5 column (Amersham 
Pharmacia Biotech) equilibrated in MonoQ buffer. After washing, the column was 
developed with a linear salt gradient to 700 mM NaCl in MonoQ buffer and fractions of 1 
ml were collected. Aliquots of 10 µl from each fraction were used in in vitro ATF2 kinase 
assays. 
Preparation of cellular fractions. For cell fractionation experiments, lysates were prepared 
from 9 cm dishes that were rinsed twice with ice-cold phosphate buffered saline (PBS) and 
scraped in 1 ml of cold RIPA buffer [30 mM Tris–HCl pH 7.5, 1mM EDTA, 150 mM 
NaCl, 0.5% Triton X-100, 0.5% Na-DOC, 1 mM sodium orthovanadate, 10 mM sodium 
fluoride and Complete protease inhibitors (Roche)]. Nuclei were pelleted by centrifugation 
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(10 min, 14000 rpm, 4°C). Supernatants were collected and stored as cytosolic fractions. 
Nuclear pellets were washed twice with RIPA and Laemmli buffer was added. Before 
western blotting nuclear samples were sonicated and boiled. Purity of the cell fractions was 
checked by Western Blotting, using EF-1β and Lamin A antibodies as cytosolic and nuclear 
markers, respectively (Figure 4C). 
ATF2 kinase assays. For in vitro ATF2 kinase assays, equal volumes of MonoQ-fractions 
and equal amounts of protein from cytosolic or nuclear extracts were incubated at 30°C 
with 2 µg of purified GST-ATF2-N substrate (12)  and 50 µM ATP in a total volume of 60 
µl of kinase buffer [25 mM HEPES, pH 7.4, 25 mM MgCl2, 25 mM β-glycerolphosphate, 5 
mM β-mercaptoethanol and 100 µM sodium orthovanadate]. When indicated, kinase assays 
were performed in the presence of vehicle (DMSO) or inhibitor SB203580 (2.5 µM). 
Reactions were terminated by the addition of 20 µl of 4x Laemmli buffer and subsequently 
analyzed by SDS–PAGE/immunoblotting with phospho-specific ATF2-Thr71 antibodies. 
Blots were quantitated using Scion Image software. 
Immunofluorescence. Cells were grown on coverslips. After stimulation, cells were washed 
twice with ice-cold PBS and subsequently fixed in 3.7% formaldehyde in PBS for 15 
minutes at room temperature. Coverslips were washed with Tris buffered saline [TBS; 25 
mM Tris, 100 mM NaCl, 5 mM KCl, 0.7 mM CaCl2.2H2O, 0.5 MgCl2.6H2O] and 
permeabilised for 5 minutes with 0.1% Triton X-100 in TBS, subsequently washed with 
0.2% BSA/TBS, blocked for 30 minutes in 2% BSA/TBS at room temperature and then 
incubated overnight at 4°C with primary antibodies diluted 1:250 in 0.2% BSA/TBS. After 
0.2% BSA/TBS washes, coverslips were incubated with appropriate secondary antibodies 
diluted 1:100 in 0.2% BSA/TBS for 2 hrs at room temperature. Thereafter coverslips were 
washed sequentially with 0.2% BSA/TBS and TBS, mounted in DAPI-containing 
Vectashield solution (Vector Laboratories) and fixed with nail polish. Fluorescence was 
detected using a Leica DM-RXA microscope. Pictures were acquired as color images 
(MERGE) and prepared using Photopaint and Coreldraw software. 
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The stimulation of cells with physiological concentrations of insulin induces a variety 
of responses, like an increase in glucose uptake, induction of glycogen and protein 
synthesis, and gene expression. One of the determinants regulating insulin-mediated 
gene expression may be activating transcription factor 2 (ATF2). Insulin activates 
ATF2 by phosphorylation of Thr69 and Thr71 via a two-step mechanism, in which 
ATF2-Thr71-phosphorylation precedes the induction of ATF2-Thr69+71-
phosphorylation by several minutes. We previously found that in JNK-/- fibroblasts 
cooperation of the ERK1/2 and p38-pathways is required for two-step ATF2-
Thr69+71-phosphorylation in response to growth factors. As JNK is also capable of 
phosphorylating ATF2, we assessed the involvement of JNK, next to ERK1/2 and p38 
in the insulin-induced two-step ATF2-phosphorylation in JNK-expressing A14 
fibroblasts and 3T3L1-adipocytes. The induction of ATF2-Thr71-phosphorylation was 
sensitive to MEK1/2-inhibition with U0126 and this phosphorylation coincided with 
nuclear translocation of phosphorylated ERK1/2. Use of the JNK-inhibitor SP600125 
or expression of dominant negative JNK-activator SEK1 prevented the induction of 
ATF2-Thr69+71-, but not ATF2-Thr71-phosphorylation by insulin. ATF2-dependent 
transcription was also sensitive to SP-treatment. Abrogation of p38-activation with 
SB203580 or expression of dominant negative MKK6 had no inhibitory effect on these 
events. In agreement with this, the onset of ATF2-Thr69+71-phosphorylation 
coincided with the nuclear translocation of phosphorylated JNK. Finally, in vitro 
kinase assays using nuclear extracts indicated that ERK1/2-preceded JNK-
translocation. We conclude that sequential activation and nuclear appearance of 
ERK1/2 and JNK rather than p38 underlies the two-step insulin-induced ATF2-
phosphorylation in JNK-expressing cells.  
 
Insulin elicits complex responses in the body in order to maintain glucose and lipid 
homeostasis. Dependent on the target tissue, insulin regulates a variety of responses, 
including glucose uptake, glycogen, protein and lipid synthesis and gene expression. Next 
to the widely studied effects of insulin on the Forkhead/FOXO-transcription factors, also 
phosphorylation of activating transcription factor 2 (ATF2), may contribute to the effects of 
insulin on gene expression (1;2). 
 ATF2 is a ubiquitously expressed member of the cAMP-responsive element 
(CRE)-binding protein family of basic region-leucine zipper (bZIP) transcription factors 
also including CREB (3) and ATF3, ATF4, ATF6 and B-ATF (4;5). ATF2 can form homo- 
and heterodimers with other ATF-family members (5), but also with the activating protein-
1 (AP-1) family member cJun (6). The various dimer compositions confer a large repertoire  
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of target genes on ATF2. Described ATF2 target-genes include cJun, cyclins A and D1, 
ATF3, Tumor Necrosis Factor α (TNFα) and peroxisome proliferator-activated receptor γ 
co-activator 1α (PGC1α) (7-13).  
In the absence of stimuli, ATF2 is pre-bound to DNA (13;14) and held in an 
inactive conformation (15). Phosphorylation of residues within the activation domain leads 
to ATF2 transcriptional activation (16-18). In particular, phosphorylation of two threonine 
(Thr) residues, Thr69 and Thr71, seems to be required and sufficient for transcriptional 
activation of ATF2 (7;19).  
We previously reported for mouse fibroblasts expressing the human insulin 
receptor that insulin induces ATF2-activation via phosphorylation of Thr69 and Thr71 via a 
two-step mechanism (2). Notably, this mechanism involves cooperation of two different 
pathways. Studies in JNK1,2 -/- embryonic fibroblasts indicated that the ERK1/2-pathway 
mediates the induction of ATF2-Thr71-phosphorylation, whereas induction of ATF2-
Thr69-phosphorylation involves the activity of the p38-pathway (2).  
However, JNK is expressed in most cell types and is known to be capable of 
phosphorylating ATF2 (7;19;20). In addition, purification of endogenous insulin-activated 
ATF2-kinases identified JNK, next to ERK and p38 as putative candidates (2). These 
observations prompted us to further determine the contribution of JNK, next to ERK1/2 and 
p38 in insulin-induced ATF2-phosphorylation in JNK-expressing A14 fibroblasts and 
3T3L1 adipocytes. These cell-types were used as representatives of the two major types of 
insulin-responses: A14 cells respond primarily mitogenic, whereas 3T3L1 adipocytes 
respond more metabolically to insulin.  
We studied in vivo and in vitro induction of ATF2-Thr71 and ATF2-Th69+71-
phosphorylation at various time-points after insulin stimulation using pharmacological 
inhibitors of the JNK, ERK1/2 and p38-pathways as well as overexpression of dominant 
negative upstream kinases regulating the activity of JNK and p38. In addition, we examined 
the insulin-induced nuclear translocation of these kinases by immunofluorescence and 
assessed nuclear fractions for the presence of in vitro nuclear ATF2-kinase activity that 
could be ascribed to JNK, ERK1/2 or p38.  
 
Results 
Differential onset of insulin-induced ATF2-Thr71 and ATF2-Thr69+71-phosphorylation. 
Insulin-treatment of A14 fibroblasts induced the phosphorylation of ATF2 on Thr71 within 
2-4 minutes, while phosphorylation of ATF2-Thr69+71 was only achieved at 7-10 minutes 
after addition of insulin (Figure 1A).  A comparable situation was found in 3T3L1 
adipocytes, in which insulin-induced ATF2-Thr71–phosphorylation was found after 4 
minutes and preceded the induction of ATF2-Thr69+71-phosphorylation (Figure 1B). In 
contrast, the induction of ATF2-Thr69+71-phosphorylation in response to osmotic shock 
(O.S.) was not preceded by ATF2-Thr71-phosphorylation (Figure 1C).  The induction of 
ATF2-Thr69+71-phosphorylation was accompanied by a retarded mobility of the protein 
on ATF2-immunoblot, which was preceded by the induction of an intermediate form after 4 
minutes of insulin-treatment (Figure 1D). The induction of this intermediate form coincided 
with the onset of ATF2-Thr71-phosphorylation and underscores the concept that in 
response to insulin-treatment the ATF2 protein undergoes a transition from the non-
phosphorylated form to the ATF2-Thr69+71-phosphorylated form via an intermediate 




Figure 1. Differential onset of insulin-induced ATF2-Thr71 and ATF2-Thr69+71 phosphorylation. Serum-starved 
A14 cells (A) or 3T3L1 adipocytes (B) were treated with 10 nM insulin (INS). Total cell lysates were prepared at 
indicated time-points and analyzed by Western blotting using phospho-specific ATF2-Thr71, ATF2-Thr69+71 
antibodies. The faster migrating bands recognized by the phospho-specific ATF2-antibodies seem to represent 
shorter, alternatively spliced, ATF2 products (2). (C) Cell lysates were prepared from A14 cells treated with 0.5 M 
NaCl (osmotic shock; O.S.) and immunoblotted as described for A and B. (D) Cell lysates prepared from insulin-
treated A14 cells as described above were used for extended electrophoresis and subsequently blotted using ATF2-
specific antibody. 
 
Differential onset of insulin-induced MAPK-phosphorylation. 
Upon examining the time-course of ERK1/2, p38 and JNK-activation in A14 fibroblasts, 
we found that ERK1/2 was phosphorylated within 2 minutes of insulin-treatment (Figure 
2A). This phosphorylation was accompanied by in vitro ATF2-directed kinase activity in 
ERK-immunoprecipitates (Figure 2B). Also some phosphorylation of p38 and ATF2-
directed kinase activity in p38-immunoprecipitates was observed within 2-4 minutes of 
insulin-treatment of A14 fibroblasts (Figures 2A and B).   
Figure 2. Time course of insulin-induced MAPK-phosphorylation.  (A) Lysates from serum-starved A14 cells 
were prepared at the indicated time points after 10 nM insulin-treatment (INS) and were examined for 
phosphorylation of ERK1/2, p38 and JNK by immunoblotting with phospho-specific antibodies. (B) ERK1/2-, 
p38- and JNK-immunoprecipitates were analyzed for ATF2-directed kinase activity in an in vitro kinase using 
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The onset of JNK-phosphorylation was delayed compared to ERK- and p38-
phosphorylation and was observed after 7 minutes of insulin-treatment. The 
phosphorylation associated with stimulation of ATF2-kinase activity in JNK-
immunoprecipitates (Figure 2A and B). 
 
Early insulin-induced ATF2-Thr71 phosphorylation is sensitive to inhibition of the MEK-
ERK pathway. As both ERK1/2- and p38-activation coincided with the onset of ATF2-
Thr71-phosphorylation, we analyzed the involvement of these MAPKs using 
pharmacological inhibitors in A14 fibroblasts. Inhibition of p38 using SB203580 (21) had 
no effect on the induction of ATF2-Thr71 phosphorylation by insulin (Figure 3A). 
However, prevention of ERK1/2-phosphorylation by the MEK1/2-inhibitor U0126 (22) 
completely abrogated the induction of ATF2-Thr71 phosphorylation (Figure 3A) and the 
appearance of the retarded (intermediate) form of ATF2 in response to 4 minutes insulin-
treatment (data not shown). Comparable results were obtained in 3T3L1 adipocytes: U0126 
prevented insulin-induced increase in ATF2-Thr71-phosphorylation, and pre-treatment with 




Figure 3. Early insulin-induced ATF2-Thr71 phosphorylation is sensitive to inhibition of the MEK1/2-ERK1/2 
pathway. Serum-starved A14 cells (A) or 3T3L1 adipocytes (B) were incubated with 10 µM U0126 (U; 15 
minutes) or 2.5 µM SB203580 (SB; 30 minutes) before insulin-stimulation (INS; 10 nM) for 4 minutes. Total 
ATF2 and ATF2-Thr71-phosphorylation levels were determined by immunoblotting with specific antibodies. (C) 
A14 cells were treated with inhibitors as described above, prior to stimulation with 10 nM of insulin for 4 minutes. 
Subsequently, cells were fixed and stained with phospho-specific ATF2-Thr71 antibodies followed by FITC-
conjugated secondary antibodies (green). DNA was stained with DAPI (blue). Full-colour illustration can be found 
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In line with these data, immunofluorescence experiments on A14 cells demonstrated 
nuclear phospho-ATF2-Thr71 immunoreactivity detected after 4 minutes of insulin-
treatment, which was abolished upon pre-treatment with U0126, but not with SB203580 
(Figure 3C). The nuclear localization of ATF2 did not change during the insulin-stimulation 
(data not shown). Collectively, these results suggest that ERK1/2, rather than p38 is 
responsible for the insulin-induced phosphorylation of nuclear ATF2 on Thr71 after 4 
minutes of stimulation.  
 
 
Cooperation of ERK1/2 with p38 or JNK is required for ATF2-Thr69+71-phosphorylation 
in vitro. When we analyzed lysates prepared from A14 cells treated for 4 minutes with 
insulin, predominantly ATF2-Thr71 directed kinase activity was found (Figure 4A). This is 
in line with the observation that ERK1/2 can only phosphorylate ATF2 on Thr71 and not 
on Thr69 (2;23). In lysates prepared after 15 minutes of insulin-stimulation, ATF2-Thr71 
directed kinase activity was similar to that found in 4 min lysates, but the level of ATF2-
Thr69+71 directed kinase activity was markedly increased (Figure 4A).  To purify the 
kinase(s) responsible for the induction of ATF2-Thr69+71 phosphorylation, MonoQ 
fractionation was performed on lysates prepared after 15 min of insulin stimulation, and the 
obtained fractions were analyzed for the presence of ATF2-Thr71 directed versus ATF2-
Thr69+71 directed kinase activity (2). Approximately 90% of the input ATF2-Thr71 
directed kinase activity was recovered after anion-exchange chromatography, and the 
majority of this fraction (80%) co-purified with fractions, containing ERK1/2 (2). The 
remaining ATF2-Thr71 directed kinase activity was recovered in fractions co-purifying 
with JNK and p38 respectively (2). These fractions also contained ATF2-Thr69+71 
directed kinase activity. However, in contrast to the almost complete recovery of ATF2-
Thr71 directed kinase activity, only 5% of the input ATF2-Thr69+71 directed kinase 
activity was recovered in the fractions containing JNK and p38 (2). Comparable results 
were obtained for fractionation of lysates from 3T3L1 adipocytes (data not shown). 
Collectively, these findings raised the possibility that maximal induction of ATF2-
Thr69+71-phosphorylation by insulin requires cooperation of ERK1/2 with p38 and/or 
JNK. To test this possibility, we added partially purified ERK1/2 to the kinase assays on 
fractions co-purifying with JNK and p38. Indeed, the weak insulin-induced ATF2-Thr71-
directed and Thr69+71-directed kinase-activities co-purifying with p38 and JNK were 
greatly enhanced by addition of ERK1/2-fraction to the assay (Figure 4B). Similar results 
were obtained upon addition of recombinant ERK1/2 to the kinase assay (data not shown). 
Together, these findings suggest that phosphorylation of ATF2 on Thr69 by p38 and/or 








Figure 4. Cooperation of ERK1/2 with p38 or JNK is required for efficient insulin-induced ATF2-Thr69+71-
phosphorylation. (A) Lysates from serum-starved A14 fibroblasts treated with 10 nM insulin (INS) for the 
indicated times were used in ATF2-directed in vitro kinase assays. Site-specific phosphorylation of GST-ATF2 
was determined by Western blotting using ATF2-Thr71 and ATF2-Thr69+71 phospho-specific antibodies, 
respectively. (B) MAPK-containing MonoQ fractions of lysates of 15-minute insulin-treated serum-starved A14 
cells were used in in vitro ATF2-directed kinase assays for 1hr. Site-specific phosphorylation of GST-ATF2 was 




Inhibition of JNK, but not p38, abrogates insulin-induced ATF2-Thr69+71 phosphorylation 
and activation. To determine the involvement of p38 and JNK in insulin-induced 
phosphorylation of ATF2 in intact cells, we used SB203580 and SP600125 (24) to inhibit 
p38 and JNK, respectively. As shown in Figure 5A and 5B, insulin-induced ATF2-
Thr69+71-phosphorylation was abrogated by SP600125, but not SB203580, in both A14 
fibroblasts and 3T3L1 adipocytes. Notably, we observed some inhibition of ATF2-Thr71-
phosphorylation by SP600125 even under conditions when JNK is not activated, i.e. under 
basal conditions and at 4 minutes after insulin addition, indicating non-specific side-effects 
of this inhibitor (Figure 5A). ATF2 band-shift analysis corroborated these results: the 
slowest migrating (Thr69+71 phosphorylated) form of ATF2 found after 10 minutes was 
not affected by SB203580, but shifted back to the intermediate form in the presence of 
SP600125 (Figure 5A).  
 Similar results were found with the use of dominant negative upstream kinases of 
p38 and JNK: MKK6-KM and SEK1-KR, respectively (see Figure 5C): Overexpression of 
SEK1-KR abrogated only the insulin-induced ATF2-Thr69+71 phosphorylation but not the 
Thr71-phosphorylation found after 15 minutes of insulin-stimulation. Overexpression of 
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Figure 5. Inhibition of JNK, but not p38, abrogates insulin-induced ATF2-Thr69+71 phosphorylation. Serum-
starved A14 fibroblasts (A) or 3T3L1 adipocytes (B) were incubated for 30 minutes with DMSO, 2.5 µM 
SB203580 (SB), 10 µM SP600125 (SP) or SB+SP prior to stimulation with 10 nM insulin (INS) for the indicated 
times. Phosphorylation of ATF2-Thr71, ATF2-Thr69+71, JNK, p38 and ERK1/2 was determined with phospho-
specific antibodies. (C) A14 fibroblasts were transfected with either an empty vector (e.v.) or expression vectors 
for epitope-tagged dominant negative MKK6-KM or SEK1-KR together with pBabe-puro and pMT2-HA-ATF2. 
Puromycin-resistant cells were selected, serum-starved overnight and subsequently stimulated with 10 nM insulin 
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Immunofluorescence experiments showed that 10 minutes of insulin-treatment increased 
nuclear ATF2-Thr69+71 immunoreactivity compared to 4 minutes and untreated A14 cells, 
and that this immunoreactivity was sensitive to SP600125 (Figure 6A). 
To determine whether modulation of insulin-induced ATF2-Thr69+71-
phosphorylation affected ATF2-mediated transcription accordingly, we examined the 
insulin-induced activation of a GAL4-ATF2-dependent luciferase reporter. Insulin-induced 





Figure 6. Inhibition of JNK, but not p38, abrogates the insulin-induced ATF2-phosphorylation and activation. (A) 
Serum-starved A14 cells were treated with inhibitors as described above prior to stimulation with 10 nM insulin 
(INS) for the indicated times. Cells were fixed and stained with antibodies for Thr69+71-phosphorylated ATF2 
followed by FITC-conjugated secondary antibodies (green). DNA was stained with DAPI (blue). (B) Insulin-
induced ATF2 transcriptional activity was examined in a GAL4-dependent luciferase reporter assay using the 
activation domain of ATF2 fused to the GAL4 DNA binding domain (19). Cells were transiently transfected and 
grown for 8 hours, subsequently serum-starved in DMEM containing 0.5% FBS O/N and treated for 30 minutes 
with vehicle or inhibitors SB203580 or SP600125 before adding insulin (INS; 10 nM). Cells were lysed 16 hrs 
later and luciferase activity was determined. The relative firefly luciferase activity is depicted as the mean 
enhancement of promoter activity in the absence or presence of insulin and/or inhibitors +/- the SD of three 
independent experiments performed in triplicates. Note the different scaling of the left and right y-axis. ** P = 















































































The onset of ATF2-Thr71 and ATF2-Thr69+71-phosphorylation associates with nuclear 
translocation of ERK1/2 and JNK. The experiments described above suggest that 
cooperation of ERK1/2 with JNK, rather than with p38, is required for insulin-induced two-
step ATF2-Thr69+71-phosphorylation. To corroborate these findings we examined whether 
ERK1/2 and JNK translocate to the nucleus in response to insulin. We found that within 4 
minutes, insulin induced the phosphorylation and nuclear translocation of ERK1/2 
(ERK1/2-PP; See Figure 7A). U0126 pre-treatment strongly inhibited the ERK1/2-PP 
signal and reduced nuclear staining found with a pan-ERK1/2 antibody (Figure 7A and data 




Figure 7. Time course of nuclear translocation of ERK1/2 and JNK. Serum-starved A14 cells were incubated with 
DMSO, 10 µM U0126 (U) for 15 minutes or 10 µM SP600125 (SP) for 30 minutes prior to stimulation with 10 
nM insulin (INS) for the indicated times. Cells were fixed and stained with antibodies for (A) phosphorylated ERK 
(ERK-PP) or (B) phosphorylated JNK (JNK-PP) and FITC-conjugated secondary antibodies (green). DNA was 























Despite the high a-specific background-level of (non-nuclear) phosphorylated JNK (JNK-
PP)-signal in the absence of insulin, no increase in JNK-PP staining could be detected after 
4 minutes of insulin-treatment (Figure 7B). The amount of JNK-PP in the nucleus was 
substantially increased after 10 minutes of insulin-stimulation and this response was 
inhibited by SP600125 (Figure 7B).  
In line with the immunofluorescence data, we found that nuclear extracts prepared 
from cells after 4 minutes of insulin stimulation contained predominantly ATF2-Thr71-
directed kinase activity (Figure 8A). This ATF2-Thr71-directed activity could be abrogated 
by addition of ERK-inhibitor 5-iodotubercidin (Itu (25)) and was absent in nuclear extracts 
from U0126-treated cells (data not shown). The ATF2-Thr71-directed kinase activity in 
these nuclear extracts was not affected by SP600125 or SB203580 (Figure 8A).  
Nuclear extracts obtained after 10 minutes of insulin-stimulation contained both 
ATF2-Thr71- and ATF2-Thr69+71-directed kinase activity (Figure 8B). Addition of the 
JNK-inhibitor SP600125 only abrogated the ATF2-Thr69+71-phosphorylation, but not the 
ATF2-Thr71-directed activity (Figure 8B).  SB203580 did not affect the ATF2-Thr69+71 






Figure 8. Sequential appearance of ERK1/2- and JNK-dependent ATF2-directed nuclear kinase activities. Serum-
starved A14 cells stimulated with 10 nM insulin for 4 minutes (A) or 10 minutes (B). Nuclear proteins were 
extracted and used in in vitro ATF2-directed kinase assays for 2 hrs in the presence of DMSO or inhibitors 2.5 µM 
SB203580 (SB), 5 µM SP600125 (SP) or 5 µM 5-iodotubercidin (Itu). Site-specific phosphorylation of GST-
ATF2 was determined by Western blotting using ATF2-Thr71 and ATF2-Thr69+71 phospho-specific antibodies. 
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The present study addresses the activation of the transcription factor ATF2 by insulin. It 
extends our previous findings (2) by addressing the mechanism via which insulin 
accomplishes this activation in A14 cells and 3T3L1 adipocytes. The results of this study 
suggest the following model for the induction of ATF2-Thr69+71 phosphorylation in 
response to insulin (summarized in Figure 9): within 2-4 minutes, insulin induces activation 
of ERK1/2, which translocates to the nucleus and mediates ATF2-Thr71-phosphorylation. 
Between 5-10 minutes after the addition of insulin, JNK is activated, translocates to the 
nucleus and mediates Thr69-phosphorylation of phospho-Thr71-ATF2, thereby activating 
the transcription factor. We propose that the sequential activation and subsequent nuclear 
appearance of ERK1/2 and JNK are rate limiting for the two-step phosphorylation of 
ATF2-Thr69+71 in response to insulin. 
Previously, we reported that in JNK-/- cells, the ERK1/2- and the p38-pathways 
cooperate in the growth factor-induced phosphorylation of ATF2-Thr69+71 (2). Although 
this study indicates that JNK may be dispensable for insulin-mediated ATF2-
phosphorylation, pharmacological inhibition of p38 in JNK-expressing cells had no 
inhibitory effect on the induction ATF2-phosphorylation, suggesting that JNK rather than 
p38 regulates this response. 
Accordingly, various studies have identified JNK as a bona fide ATF2-kinase 
(2;7;19;20;23). An important finding of the present study, however, is that JNK 
predominantly functions as ATF2-Thr69-kinase for ATF2 already phosphorylated on 
Thr71, in the proposed two-step ATF2-Thr69+71 phosphorylation-mechanism induced by 
insulin. In contrast, in response to inducers of cellular stress like UV, methyl methane 
sulphonate (MMS), osmotic shock and TNFα, the onset of ATF2-Thr69+71 coincides with 
the onset of ATF2-Thr71-phosphorylation, and this process seems completely JNK-
dependent in JNK-expressing cells (2;7;23 and data not shown).  
 
 
Figure 9. Proposed model for insulin-induced ATF2-activation in A14 cells and 3T3L1 adipocytes. Insulin 
induces activation of ERK1/2 within 2-4 minutes. ERK1/2 subsequently translocates to the nucleus, where it 
mediates ATF2-Thr71-phosphorylation. Subsequently JNK is activated, translocates to the nucleus and efficiently 













This raises the question whether activation of JNK alone may be sufficient for the induction 
of ATF2-phosphorylation in response to insulin-treatment. However, the data shown here 
are indicative that also ERK1/2 activation seems to biologically relevant for insulin-
mediated two-step ATF2-phosphorylation. Biochemical evidence for its involvement is 
provided by changes in electrophoretic mobility of the ATF2 protein during the course of 
insulin-mediated phosphorylation. After insulin stimulation, the ATF2-protein undergoes a 
transition via an ATF2-Thr71 phosphorylated form to an ATF2-Thr69+71 phosphorylated 
form. More importantly, pharmacological inhibition of ERK-activation prevented early 
ATF2-Thr71 phosphorylation and the accompanying retarded mobility of the protein. In 
addition, ERK1/2- and ATF2-Thr71-phosphorylation are found several minutes before 
JNK-activation and ATF2-Thr69+71 phosphorylation were detectable. Collectively, these 
findings highlight the importance of ERK1/2 for insulin-induced ATF2-phosphorylation 
and provide support for our model. 
We and others have demonstrated that ERK preferentially phosphorylates ATF2 
on Thr71, whereas the kinase seems incapable to efficiently mediate ATF2-Thr69 
phosphorylation (2;23). Therefore, cooperation with another kinase seems required for 
induction of ATF2-Thr69+71 phosphorylation in response to insulin. Interestingly, while 
MonoQ fractionation of lysates from osmotic-shock treated cells yielded similar recoveries 
for ATF2-Thr69+71 and ATF2-Thr71 directed kinase activities, in cell extracts from 
insulin-treated cells, only ~5% of the ATF2-Thr69+71 directed in vitro kinase activity was 
recovered, in contrast to ~80% recovery of ATF2-Thr71 directed activity (for details see 
reference (2)) Importantly, the weak insulin-induced ATF2-Thr69+71 kinase activities, 
which co-purified with JNK and p38 respectively, were greatly enhanced by the addition of 
ERK1/2 to the kinase reaction. Collectively, these findings strongly suggest that insulin-
activated MAP kinases cooperate to induce efficient ATF2-Thr69+71 phosphorylation and 
provide strong support for our two-step model. 
Previously, Waas and coworkers (26) found that recombinant active p38 
phosphorylates GST-ATF2 via a two-step (double collision) mechanism, involving the 
dissociation of mono-phosphorylated Thr71-ATF2 or Thr69-ATF2 from the enzyme after 
the first phosphorylation step. Importantly, these authors found that mono-phosphorylation 
of ATF2-Thr69 strongly reduces the phosphorylation rate of Thr71, whereas, mono-
phosphorylation of Thr71 does not reduce the rate of Thr69 phosphorylation (26). Thus, 
efficient phosphorylation of ATF2 by recombinant active p38 only occurs in the order 
Thr71  Thr69+71. In our model, phosphorylation of ATF2-Thr71 by ERK1/2 might 
prime ATF2 for subsequent efficient ATF2-Thr69-phosphorylation. As described above, 
the kinase assays on MonoQ fractions indicate that both p38 and JNK can indeed enhance 
the phosphorylation of ATF2-Thr69+71 in the presence of activated ERK1/2 in vitro. In 
cultured cell lines expressing both kinases, however, JNK rather than p38 seems to mediate 
this second phosphorylation. Several lines of evidence point in this direction: First, 
chemical inhibition of JNK-activity with SP600125, or prevention of JNK-activation by 
overexpression of dominant negative SEK1 abrogated only the Thr69+71-phosphorylation 
in response to insulin. Second, prevention of p38-activation by overexpression of dominant 
negative MKK6 or inhibition of p38 by SB203580 failed to affect insulin-mediated ATF2-
phosphorylation in JNK-expressing cells. In part, the absence of the inhibitory effect of SB 
could be ascribed to an enhanced activation of JNK which was observed in the presence of 
this inhibitor ((2) see also Figure 5 and Supplementary Figure S1). However, simultaneous 
addition of SB203580 and SP600125 had the same effect as SP600125 alone, suggesting 
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that this is not the case. In addition, we could not obtain evidence for nuclear translocation 
of activated p38 in insulin-treated cells neither in immunofluorescence assays nor in in vitro 
kinase assays on nuclear extracts.  
To exclude the possibility that SB203580 was unable to inhibit p38, we analyzed 
inhibition of p38-activity by SB203580 in vitro and in vivo. In in vitro kinase assays the 
SB-compound completely abrogated ATF2-directed kinase activity found in p38-containing 
MonoQ-fractions of insulin-stimulated A14 fibroblasts (data not shown). Also, we found 
that phosphorylation of p38's downstream nuclear target MAPKAPK2 (MK2 (27)) in 
response to insulin in JNK-/- cells was sensitive to SB203580-treatment (data not shown). 
Interestingly, although in A14 fibroblasts p38-activity was induced by insulin and reduced 
by SB203580-treatment, no MK2-phosphorylation could be detected in these cells (Figure 
S1). In contrast, O.S. did induce robust phosphorylation of both p38 and MK2, which were 
reduced and abrogated, respectively by SB203580-treatment (Figure S1). These 
observations suggest that the SB203580-compound was functional in in vitro and in vivo 
assays. In addition, it seems that in JNK-containing A14 cells, insulin-induced phospho-p38 
is confined to the cytosol or does not reach its nuclear target MK2, while it does after O.S.-
stimulation. 
Collectively, these data support the idea that JNK rather than p38 is responsible 
for the second phosphorylation event, and that p38 seems only capable of inducing ATF2-
phosphorylation under conditions that JNK is genetically absent. 
 
Materials and Methods 
Cell culture and cell stimulation. A14 cells (NIH 3T3 fibroblasts overexpressing the human 
insulin receptor (28)) were cultured in Dulbecco’s modified Eagle’s medium (DMEM) 
containing 9% fetal bovine serum (FBS) and antibiotics. 3T3L1 fibroblasts were obtained 
from ATCC and differentiated to adipocytes as described (29). Briefly, 3T3L1 cells were 
grown to confluence. Two days post-confluence, differentiation was induced by culturing 
cells for 2 days on DMEM/FBS supplemented with 10 µg/ml of bovine insulin (Sigma), 
0.25 µM dexamethasone (Sigma) and 0.5 mM 3-isobutyl-1-methylxanthine (Sigma), 
followed by DMEM/FBS containing only insulin (10 µg/ml). Differentiated adipocytes 
were maintained for another 6 days in DMEM/FBS prior to use. Before cell-stimulations, 
the cells were serum-starved (DMEM w/ 0.5% FBS) for 16h. When inhibitors were used, 
cells were pre-treated for 30 minutes with 10 µM SP600125 (Biomol) or 2.5 µM SB203580 
(Promega) or for 15 minutes with 10 µM U0126 (Promega), before addition of bovine 
insulin to 10 nM or NaCl (osmotic stress; O.S.) to 500 mM. 
Transient transfection and luciferase assays. For overexpression experiments, A14 cells 
were co-transfected in 6 well plates with a total of 1.5 µg of DNA per well; 0.875 µg of 
either a carrier vector or expression vectors encoding epitope-tagged dominant negative 
MKK6-K82M or SEK1-K129R (kindly provided by Dr J. Kyriakis), 0.5 µg pMT2-HA-
ATF2 (2) and 0.125 µg pBabe-puro using FUGENE6 transfection reagent (Roche) 
according to suppliers protocol. Cells were selected with 3 µg/ml of puromycin (Sigma) for 
3-5 days, after which cells were serum-starved overnight, stimulated with 10 nM insulin for 
15 minutes and lysed and blotted as described above. 
For GAL4-luciferase assays, A14 cells were transfected in 6 well plates using the 
DEAE–dextran method as described (30). For each well 0.25 µg pGl3-GAL4-E4-luciferase 
reporter (2) was co-transfected with 1 µg of carrier vector psp64 and 1 µg of either pC2-
Gal4-ATF2-TAD (19) or the carrier vector. Briefly, DNA was mixed in 1 mg/ml DEAE-
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dextran-supplemented TBS [25 mM Tris; pH 7.4, 150 mM NaCl, 5 mM KCl, 0.7 mM 
CaCl2 and 0.5 mM MgCl2] and added to cells. After a 30-minute incubation, cells were 
washed and DMEM/FBS was added. After 8 hours, cells were serum-starved in DMEM 
containing 0.5% FBS and 24 hours after transfection cells were pre-treated with inhibitors 
before adding insulin (to 10 nM). 16 hours later, cells were lysed in luciferase lysis buffer 
[25 mM Tris, pH 7.8, 2 mM dithiotreitol, 2 mM 1,2-diaminocyclohexane-N,N,N',N'-
tetraacetic acid, 10% glycerol and 1% Triton X-100] and luciferase activity was determined 
according to the manufacturer's protocol (Promega). 
Western blot analysis and antibodies. Whole cell lysates were prepared from 9 cm dishes 
that were rinsed twice with ice-cold phosphate-buffered saline (PBS) and lysed in 750 µl 
Laemmli sample buffer. Proteins were separated on polyacrylamide slab gels and 
transferred to Immobilon (Millipore). Blots were stained with Ponceau S before blocking to 
verify equal loading and appropriate protein transfer. Filters were incubated with antibodies 
as described previously (2). The antibodies used were: Lamin A and phospho-specific 
ATF2-Thr69+71, ATF2-Thr71, p38-Thr180/Tyr182, ERK1/2-Thr202/Tyr204 (all 
polyclonal) and JNK-Thr183/Tyr185 monoclonal (all from Cell Signaling Technology); 
p38 (N-20), ATF2 (C-19) and ERK1 (K-23) (Santa Cruz) and secondary antibodies: goat 
anti-rabbit and goat anti-mouse IgG–HRP conjugate (Promega). The total JNK and EF-1β 
antibodies were described previously (2;31). For ATF2 band shift analysis, immunoblots 
were prepared after separation of proteins on large 7% polyacrylamide slab gels, and 
incubated with ATF2 (C-19) antibody. 
MonoQ/anion-exchange chromatography. Anion-exchange chromatography was performed 
essentially as described previously (2). Briefly, stimulated cells were scraped in MonoQ 
lysis buffer [20 mM Tris (pH 7.0), 0.27 M sucrose, 1 mM EDTA, 1 mM EGTA, 1% Triton 
X-100, 10 mM sodium β-glycerolphosphate, 50 mM NaF, 5 mM sodium pyrophosphate, 1 
mM sodium orthovanadate, 0.1% (v/v) β-mercaptoethanol and Complete protease inhibitors 
(Roche Biochemicals)]. Lysates of six 9-cm dishes (~8000 mg protein) were diluted 
twofold with MonoQ buffer [50 mM Tris.Cl (pH 7.5), 1 mM EDTA, 1 mM EGTA, 5% 
(v/v) glycerol, 0.03% (w/v) Brij-35, 1 mM benzamidine, 0.3 mM sodium orthovanadate, 
and 0.1% (v/v) β-mercaptoethanol] and applied to a MonoQ HR 5/5 column (Amersham 
Pharmacia Biotech) equilibrated in MonoQ buffer. After washing, the column was 
developed with a linear salt gradient to 700 mM NaCl in MonoQ buffer and fractions of 1 
ml were collected. Aliquots of 10 µl from each fraction were used in in vitro ATF2 kinase 
assays. 
Preparation of nuclear extracts. For extraction of nuclear proteins, cell lysates were 
prepared from 9 cm dishes that were rinsed twice with ice-cold phosphate buffered saline 
(PBS) and scraped in 1 ml of cold RIPA buffer [30 mM Tris–HCl pH 7.5, 1mM EDTA, 
150 mM NaCl, 0.5% Triton X-100, 0.5% Na-DOC, 1 mM sodium orthovanadate, 10 mM 
sodium fluoride and Complete protease inhibitors (Roche)]. Nuclei were pelleted by 
centrifugation (10 min, 14000 rpm, 4°C). Supernatants were collected and stored as 
cytosolic fractions. Nuclear pellets were washed twice with RIPA and were then incubated 
on ice for 1hr with 75 µl of extraction buffer [30 mM Tris-HCl pH 7.5, 300 mM NaCl, 1 
mM EDTA with Complete protease inhibitors (Roche)] and vortexed every 5 min. After 
centrifugation, supernatants were collected and used as nuclear protein extracts. Protein 
content was determined using the BCA-kit (Pierce). Purity of the cell fractions was checked 
by Western Blotting, using EF-1β and Lamin A antibodies as cytosolic and nuclear 
markers, respectively (see supplementary Figure S2). 
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ATF2 kinase assays. For in vitro ATF2 kinase assays, equal volumes of MonoQ-fractions 
and equal amounts of protein from cytosolic or nuclear extracts were incubated at 30°C 
with 2 µg of purified GST-ATF2-N substrate (7) and 50 µM ATP in a total volume of 60 µl 
of kinase buffer [25 mM HEPES, pH 7.4, 25 mM MgCl2, 25 mM β-glycerolphosphate, 5 
mM β-mercaptoethanol and 100 µM sodium orthovanadate]. When indicated, kinase assays 
were performed in the presence of vehicle (DMSO) or inhibitors SB203580 (2.5 µM), 
SP600125 (5 µM) or iodotubercidin (Itu;5 µM (25)). Reactions were terminated by the 
addition of 20 µl of 4x Laemmli buffer and subsequently analyzed by SDS–
PAGE/immunoblotting with phospho-specific ATF2-Thr69+71 and ATF2-Thr71 
antibodies. The specificity of these antibodies has been verified previously (2;23).  
For immunoprecipitation kinase assays, RIPA cell lysates were prepared as 
described above and equal aliquots (750 µg) were nutated overnight with 10 µl of p38, 
JNK, or ERK antibodies coupled to protein A-sepharose beads (Pharmacia) at 4°C. The 
antibodies used for immunoprecipitation were: ERK 2199 (32), p38 N20 (Santa Cruz) and 
JNK1 FL (Santa Cruz). Beads were collected by centrifugation and were washed four times 
with RIPA buffer, and two times with kinase buffer. Subsequently, the beads were 
incubated with 2 µg of purified GST-ATF2-N substrate (7) and 50 µM ATP, containing 2 
µCi [γ-32P]ATP, in a total volume of 60 µl of kinase buffer for 1 at 30°C.  
Immunofluorescence. Cells were grown on coverslips. After stimulation, cells were washed 
twice with ice-cold PBS and subsequently fixed in 3.7% formaldehyde in PBS for 15 
minutes at room temperature. Coverslips were washed with Tris buffered saline [TBS; 25 
mM Tris, 100 mM NaCl, 5 mM KCl, 0.7 mM CaCl2.2H2O, 0.5 MgCl2.6H2O] and 
permeabilised for 5 minutes with 0.1% Triton X-100 in TBS, subsequently washed with 
0.2% BSA/TBS, blocked for 30 minutes in 2% BSA/TBS at room temperature and then 
incubated overnight at 4°C with primary antibodies diluted 1:250 in 0.2% BSA/TBS. After 
0.2% BSA/TBS washes, coverslips were incubated with appropriate secondary antibodies 
diluted 1:100 in 0.2% BSA/TBS for 2 hrs at room temperature. Thereafter coverslips were 
washed sequentially with 0.2% BSA/TBS and TBS, mounted in DAPI-containing 
Vectashield solution (Vector Laboratories) and fixed with nail polish. Fluorescence was 
detected using a Leica DM-RXA microscope. Pictures were acquired as color images 
(MERGE) and prepared using Photopaint and Coreldraw software. 
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Supplemental figures to Chapter 4 
 
 
SUPPL. FIG S1. Serum-starved A14 cells were treated with DMSO or 10 µM U0126 (U; 15 minutes), 2.5 µM 
SB203580 (SB; 30 minutes), 10 µM SP600125 (SP; 30 minutes) or SB and SP (B/P; 30 minutes) prior to 15 
minute-treatments with 10 nM insulin (INS) or osmotic shock (O.S.; 0.5M NaCl). Cell lysates were prepared and 








SUPPL. FIG. S2. Crude cell fractions were prepared from serum-starved, insulin-stimulated A14 fibroblasts as 
described in Materials and Methods. Cytosolic and nuclear fractions were immunoblotted using EF-1β and Lamin 
A antibodies as cytosolic and nuclear markers, respectively. No cytosolic leak could be detected in the nuclear 
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Activating transcription factor 2 (ATF2) is strongly associated with the response to 
inducers of cellular stress, like viral infection and DNA damage. However, ATF2 has 
also been identified as a component of insulin signalling, both in vitro and in vivo. 
Studies in mouse and Drosophila have linked ATF2 to the regulation of glucose and 
lipid metabolism via induction of PPARγ coactivator 1α (PGC1α) and 
phosphoenolpyruvatecarboxykinase (PEPCK) expression. This study aimed at 
detailing the role of ATF2 in insulin action and metabolic control through the 
characterization of ATF2 target genes in insulin-sensitive cell lines. Therefore, we 
analyzed the expression of 16 putative ATF2-target genes by real-time PCR in 3T3L1 
adipocytes and A14 cells. Using the JNK-inhibitor SP600125, which abrogates the 
induction of ATF2 phosphorylation by insulin, and shRNA-mediated silencing of the 
ATF2 gene, we identified ATF3, c-jun, Egr1, MKP1, and SREBP1c as insulin-induced 
ATF2-dependent genes. Furthermore, we found that the induction of adiponectin by 
insulin is JNK-dependent. 
 
Activating transcription factor 2 (ATF2), a ubiquitously expressed member of the cAMP-
responsive element binding protein family of basic region leucine-zipper transcription 
factors, has been implicated in multiple responses in mammalian cells  by regulating the 
expression of a broad spectrum of target genes (1-3). Among the ATF2 target genes are cell 
cycle regulators (cyclin A, cyclin D1), proteins related with invasion (MMP2, UPA), cell 
adhesion molecules (E-selectin, P-selectin, and VCAM), anti-apoptotic factors (Bcl-2), 
transcription factors (c-jun, ATF3, CHOP, c-fos, junB), growth factor receptors and 
cytokines (PDGFRα, IL8, Fas ligand, TNFα, IL1β, and IL6), and proteins engaged in the 
response to endoplasmic reticulum (ER) stress and DNA damage (Grp78,ATM, XPA) (1-
4). The nature of these target genes indicates a key role for ATF2 in oncogenesis and 
protection against cellular stress and DNA damage. 
 Activation of ATF2, however, is not confined to inducers of cellular stress. Also 
insulin has been shown to activate ATF2 in vitro and in vivo (5-8). Moreover, ATF2 has 
been implicated in the regulation of proteins involved in metabolic control, including 
expression of PPARγ coactivator 1α (PGC1α) in brown adipose tissue (9) and 
phosphoenolpyruvate carboxykinase (PEPCK) in the liver and white adipose tissue (10-12).  
Finally, selective ablation of ATF2 in the Drosophila fat body, the fly equivalent of 
mammalian liver and adipose tissue, not only confirms ATF2 regulation of PEPCK 
expression, but also identifies ATF2 as critical regulator of lipid metabolism (13).  
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Collectively, these findings strongly suggest that ATF2 also has an important function in 
the regulation of metabolic control by insulin.  
To detail the role of ATF2 in insulin action, the present study aimed to 
characterize insulin-regulated ATF2 target genes in 3T3L1 adipocytes and A14 fibroblasts. 
We used real-time PCR to examine the effects of insulin on the expression of 16 putative 
ATF2 targets identified in previous studies (1;3;4). To validate these genes as bona fide 
ATF2 targets, the expression of the insulin-regulated genes was subsequently studied 
following treatment with the JNK-inhibitor SP600125, which abrogates insulin-mediated 
ATF2 phosphorylation (5), and after shRNA-mediated silencing of the ATF2 gene. 
 
Results 
Regulation of gene expression by insulin. Using real-time PCR, we examined the effect of 
insulin on the expression 16 putative ATF2-target genes in 3T3L1 adipocytes. The 
candidate genes, which are listed in Table 1, were selected on the basis of previous studies 
and have regulatory functions in insulin action and lipid metabolism. Adiponectin was 
included as potential ATF2 target gene based on a promoter analysis, which identified two 
potential cyclic AMP response elements (CRE), the binding site for ATF2, at position -
3177 (TGACGTAA) and -335 (TGACGTCC), respectively.  
 
Table 1. Potential ATF2 target genes 
Target References Role in insulin action & metabolism 
Transcriptional regulators   
ATF3 (1;3;20) apoptosis 
FOXO3a (4) metabolic gene expression 
c-jun (1;3;4) proliferation 
CREB1 (1;3) metabolic gene expression 
Egr1 (4) proliferation 
HIF1α (4) Angiogenesis 
PGC1α (9) metabolic gene expression 
PPARα (4) metabolic gene expression 
SREBP1c (4) lipid metabolism 
Hormones   
adiponectin  positive regulation insulin action 
IGF2 (4) adipocyte function 
IGFBP6 (4)  
IL1β (1;21) β-cell destruction, inflammation 
TNFα (21) inhibition of insulin signalling 
Metabolic enzymes   
MKP1 (4;49) inhibition of insulin signalling 
PEPCK (10;11;13) gluconeogenesis, glyceroneogenesis 
 
 
Figure 1 shows that a 30 min incubation with insulin increased the expression of 7 genes 
(adiponectin, ATF3, c-jun, Egr1, IGFBP6, MKP1, and PEPCK), lowered the levels of 3 
genes (FOXO3a, IGF2, PPARα), and did not affect the abundance of 4 genes (CREB1, 
HIF1α, PGC1α, and SREBP1c) in 3T3L1 adipocytes. No reproducible data were obtained 
for IL1β and TNFα. Except for ATF3, all insulin-mediated alterations in gene expression, 
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both positive and negative, were transient. Compared to 30 min of insulin incubation, the 
levels of c-jun and Egr1 were lower after 60 min exposure to insulin, or had returned to 




Figure 1. Regulation of gene expression by insulin in 3T3L1 adipocytes. Serum-starved 3T3L1 adipocytes 
were kept untreated (basal; open bars), or stimulated for 30 min (30'; grey bars) or 60 min (60'; black bars) with 10 
nM insulin. Gene expression levels were determined by real-time PCR. The relative mRNA abundance (Ra) in 
untreated cells was set at 100. Data are mean ± SEM of 3 independent experiments performed in duplicate. *, 
P<0.05 versus basal. 
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We used A14 cells to substantiate the insulin-mediated induction of putative ATF2-target 
genes. Compared to 3T3L1 adipocytes, insulin increased the mRNA levels of ATF3, c-jun, 
Egr1 and MKP1 in A14 cells (Figure 2). Only in A14 cells, insulin also induced HIF1α and 
SREBP1c mRNA (Figure 2). The levels of CREB1, IGFBP6, and PGC1α were either 
lowered or unaffected by insulin (Figure 2). We did not determine the abundance of 
adiponectin and PPARα, as these metabolic genes are not expressed in A14 cells, and failed 
to obtain reproducible results for IGF2, IL1β, TNFα, and FOXO3a. Finally, whereas the 
insulin effects in 3T3L1 adipocytes were transient, the increases in gene expression in A14 
fibroblasts were more linear in time (Figure 2).  
 
 
Figure 2. Regulation of gene expression by insulin in A14 fibroblasts. Serum-starved A14 cells were kept 
untreated (basal; open bars), or stimulated for 30 min (30'; grey bars) or 60 min (60'; black bars) with 10 nM 
insulin. Gene expression levels were determined by real-time PCR. The relative mRNA abundance (Ra) in 
untreated cells was set at 100. Data are mean ± SEM of 3 independent experiments performed in duplicate. *, 
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Inhibition of JNK abrogates insulin-mediated gene induction in 3T3L1 adipocytes and A14 
cells. We have previously shown that the JNK inhibitor SP600125 blocks insulin-mediated 
ATF2 activation (5). Therefore, we used SP600125 to ascribe the induction of the insulin-
regulated genes to activation of the JNK/ATF2-pathway. As shown in Figure 3, SP600125 
completely abrogated insulin-induced ATF2-Thr69 phosphorylation both in 3T3L1 
adipocytes and A14 fibroblasts (Figure 3) without significantly affecting other components 
of insulin action, like PKB-S473 phosphorylation and the ERK1/2-dependent ATF2-Thr71 





Figure 3. Effect of SP600125 on ATF2-phosphorylation and insulin signalling. Serum-starved 3T3L1 
adipocytes and A14 fibroblasts were treated with DMSO or SP600125 (10 µM) for 30 min prior to stimulation 
with 10 nM insulin. Total cell lysates were prepared after 15 minutes and analyzed by Western blotting using 
phospho-specific ATF2-Thr71, ATF2-Thr69+71 and total ATF2 antibodies or phospho-specific antibodies 




In 3T3L1 adipocytes, SP600125 blocked the induction of adiponectin, ATF3, c-jun, Egr1, 
and MKP1, but not of IGFBP6 and PEPCK, mRNA by 30 min insulin treatment (Figure 
4A). Similarly, in A14 cells, SP600125 significantly blunted the increase in c-jun, Egr1, 
MKP1, HIF1α and SREBP1c mRNA by 60 min of insulin exposure (Figure 4B). Thus, the 
insulin-mediated induction of ATF3, c-jun, Egr1, HIF1α, MKP1, and SREBP1c, but not 
















Figure 4. Inhibition of insulin-mediated gene expression by SP600125. Serum-starved 3T3L1 adipocytes (A) 
and A14 fibroblasts (B) were treated with DMSO (open bars) or with 10 µM SP600125 (black bars) for 30 min 
prior to stimulation with 10 nM insulin for 30 min (3T3L1 adipocytes) or 60 min (A14 cells). Gene expression 
levels were determined by real-time PCR. The effect of insulin is expressed as fold over basal. Data are mean ± 
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ATF2 silencing and insulin-mediated gene induction in A14 fibroblasts. Next, we examined 
the effect of silencing of the ATF2 gene on insulin-mediated gene induction in A14 
fibroblasts. Expression of mATF2#1 or mATF2#2 downregulated ATF2 mRNA levels by 
70 and 82 %, respectively when compared to cells transfected with pSuper (Figure 5A). 
ATF2 silencing also resulted in an almost complete knock-down of ATF2 protein 
expression, but did not significantly interfere with the phosphorylation of PKB-S473 and 
ERK1/2 in response to insulin (Figure 5B). 
 Figure 5C shows that silencing of the ATF2 gene blunted the insulin-mediated 
induction of ATF3, Egr1, MKP1, and SREBP1c mRNA, and to a lesser extent c-jun 
mRNA. We did not observe induction of HIF1α by insulin in A14 cells transfected with 
pSuper (Figure 5C). 
Figure 5. Effect of ATF2 silencing on insulin signalling and insulin-mediated gene expression. A14 cells were 
transfected with pSuper (pS) or ATF2-specific shRNA (#1 and #2). A. Effect of ATF2 silencing on relative ATF2 
mRNA abundance (Ra). Data are mean± SEM of 2 independent experiments performed in duplicate. *, P<0.05 
versus pSuper. B. Western blot analysis of cells kept untreated (-) or stimulated for 15 min with 10 nM insulin (+) 
using antibodies for ATF2, phospho-specific antibodies directed against PKB-P473 and ERK1/2- P202/204. Equal 
loading was confirmed using insulin receptor β-subunit and EF1β antibodies. * marks a background band C. 
Relative mRNA abundance (Ra) of ATF2 target genes in A14 cells transfected with pSuper (open bars), 
mATF2#1 (grey bars) or mATF2#2 (black bars). The effect of 60 min incubation with 10 nM insulin is expressed 
as fold over basal. Data are mean ± SEM of 2 independent experiments performed in duplicate. *, P<0.05 versus 
pSuper. 
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Thus, in A14 cells, ATF2 contributes to the induction of ATF3, c-jun, Egr1, MKP1, and 
SREBP1c mRNA by insulin. 
 
Discussion 
To detail the role of ATF2 activation in insulin action and metabolic control, insulin-
regulated ATF2-dependent genes were characterized in both 3T3L1 adipocytes and A14 
fibroblasts. The terminally differentiated 3T3L1 adipocytes display metabolic responses, 
like insulin-mediated glucose uptake, triglyceride synthesis, and inhibition of lipolysis (14-
16), as well as secretion of adipokines (17). A limitation of 3T3L1 adipocytes is that both 
conventional gene transfer methods, like transient transfections, and lentivirus-mediated 
delivery of shRNA-constructs are inefficient in this cell type. To circumvent this problem, 
we also included A14 fibroblasts in this study. These cells respond to insulin in a more 
‘mitogenic’ manner, such as induction of the immediate early genes c-jun and c-fos, and 
DNA synthesis (18;19). Both cell types were exposed to insulin for 30-60 min, not only to 
reduce secondary responses, but also because ATF2 activation and c-jun induction occur 
within 4-10 min and 30-60 min after the addition of insulin, respectively (5;8;19). 
Potential ATF2 target genes were selected on the basis of a promoter analysis for 
CRE-binding sites, or previous studies (1;3;4;10;11;13;20;21). For a number of selected 
genes ATF3, c-jun, Egr1, MKP1, and SREBP1c, the mRNA levels were increased by 
insulin, and this induction was blunted both by the JNK-inhibitor SP600125 and by 
silencing of the ATF2 gene. In 3T3L1 adipocytes, we also found that the insulin-mediated 
induction of adiponectin was inhibited by SP600125. As this gene is not expressed in A14 
fibroblasts, we could not validate this finding using shRNAs. Activation of luciferase 
reporter constructs fused to the adiponectin promoter by ATF2-VP16, a hybrid protein in 
which the potent transactivation domain of the viral transactivator VP16 is fused to the 
carboxyl terminus of ATF2 (22), or chromatin immunoprecipitation assays, could further 
detail a role for ATF2 in the regulation of adiponectin.  
Although previous studies have identified PEPCK, PGC1α, IL1β, and TNFα (1;9-
11;13;21) as ATF2-target genes, we could not confirm a role for ATF2 in the regulation of 
these genes by insulin in A14 cells and/or 3T3L1 adipocytes. In the case of IL1β and 
TNFα, we did not obtain reproducible amplification of these genes. It seems plausible that 
these genes are not expressed in these cell types under the experimental conditions used. 
Studies in murine tissues, including the liver, have demonstrated that the primer sets used to 
amplify these genes are functional (6).  
Various possibilities may underlie the absence of regulation PEPCK and PGC1α 
expression by the insulin-ATF2 pathway. ATF2 binds to DNA either as homodimer, or as 
heterodimer with other ATF family members, like ATF3, ATF4, ATF6, and B-ATF, or c-
jun family members(1-3). In addition, at least 21 distinct isoforms of mouse ATF2 have 
been identified so far. These various isoforms combined in different (hetero)dimer 
compositions confer a large repertoire of target genes on ATF2, depending on tissue-
specific expression levels and the activating stimulus. In case of PEPCK, which was 
identified as an ATF2 target gene in rat hepatoma cells, but also in the  fat-body, the fly 
equivalent of the mammalian liver and fat tissue (10;11;13), differences in the activating 
stimulus, rather than tissue-specific factors seem to underlie the absence of gene-regulation 
by the insulin-ATF2 pathway in the cell-types examined.  
Both tissue- and stimulus-specific differences may contribute to the lack of 
PGC1α-induction by insulin in 3T3L1 adipocytes, and its downregulation in A14 
fibroblasts, as PGC1α was characterized as target of the p38-ATF2 pathway in response to 
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β-adrenergic stimulation of brown adipose tissue (9). Other insulin-activated signaling 
pathways may be dominant over the ATF2-pathway in 3T3L1 and A14 cells. For example, 
the PKB/FOXO pathway, which is strongly activated by insulin, has been shown to lower 
the expression of PGC1α (23). 
An important question arising from this study is how the identified target genes 
impact on insulin action and metabolic control. The gene most strongly induced by insulin 
in both 3T3L1 adipocytes and A14 fibroblasts, is the zinc-finger transcription factor Egr1. 
In β-cells, insulin-regulated induction of Egr1, like c-jun, regulates proliferation and 
differentiation (24-27), amongst others by Egr1-dependent induction of the homeodomain 
transcription factor pancreas duodenum homeobox-1 (PDX1), a key regulator of insulin 
expression and pancreatic β-cell development, function, and survival (25). In adipocytes, 
insulin-mediated regulation of Egr1 contributes to the induction of tissue factor and 
macrophage colony-stimulating factor, two cardiovascular risk factors (28;29). 
Furthermore, in endothelial cells, the insulin-induced Egr1-target genes, like platelet-
derived growth factor, TNFα, intracellular adhesion molecule-1, monocyte chemotactic 
protein-1, plasminogen activator inhibitor-1, and vascular adhesion molecule-1, are 
strongly linked to the development of atherosclerosis (30;31) and also expressed in 
adipocytes. Intriguingly, both in adipocytes and endothelial cells, the induction of Egr1 by 
insulin was not altered under conditions of insulin resistance (29;31). Thus, whereas the 
function of Egr1 induction in adipocytes is unclear under normal conditions, deregulation 
of this response in type 2 diabetes may contribute to the development of vascular 
complications.  
Also the role of ATF3, a transcription factor belonging to the same family as 
ATF2, in normal insulin action requires further studies. Although ATF3 has been 
implicated in the downregulation of PEPCK in the liver (32), other studies strongly link 
ATF3 to cellular damage and apoptosis. For example, the induction of ATF3 in response to 
pro-inflammatory cytokines, nitric oxide, hyperglycemia, high levels of palmitate, or 
endoplasmic reticulum stress precedes apoptosis in β-cells (11;33;34). 
 cJun is another member of the bZip-containing family of transcription factors and 
has been implicated in the regulation of cell growth and differentiation (2). cJun is an 
important dimer-partner of ATF2 (35). In addition, one of the major kinases 
phosphorylating both cJun and ATF2: JNK, is activated by insulin (5;36). Insulin-induced 
JNK-dependent cJun-phosphorylation has been reported in A14 cells ((7), BB and DMO, 
unpublished results). Thus, cJun could cooperate with ATF2 in regulating insulin-induced 
ATF2-dependent gene expression. However, it should be noted that, increasing evidence 
also supports a role for JNK in the development of insulin resistance in a number of tissues 
(reviewed in (37-39)) suggesting that cJun, perhaps in combination with ATF2, could also 
be involved in the development of insulin resistance. 
MKP1 belongs to the MAP kinase phosphatase family of dual specificity 
phosphatases, which negatively regulate the activity of MAP kinases, like JNK, p38 and 
ERK1/2 (40). Interestingly, levels of phosphorylated ATF2 in insulin-treated cells remain 
elevated when the induction of MKP1 is abolished (DMO, unpublished data). This 
observation raises the possibility that MKP1 induction may serve to prevent sustained 
ATF2 activation by insulin and dampen a prolonged expression of detrimental ATF2-target 
genes. Accordingly, MKP1 has an inhibitory effect on the production of monocyte 
chemoattractant protein 1 (MCP-1), a chemokine highly associated with the development of 
adipocyte dysfunction in insulin resistance (41).  
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The transcription factor SREBP1c is a pivotal regulator of glucose and lipid metabolism, 
amongst others by inducing the expression of glucokinase and genes involved in 
lipogenesis (42). Insulin is a known inducer of SREBP1c in various tissues (43). Although 
SREBP1c was identified as ATF2-regulated gene before (4), analysis of the insulin-
regulated part of the SREBP1c promoter did not (yet) identify putative ATF2-binding sites 
(43). It is therefore plausible that ATF2 regulates the SREBP1c promoter through the 
transcriptional co-activator p300/CBP (43;44). Like Egr1 and ATF3, however, deregulation 
of SREBP1c activity by high fat feeding, endoplasmic reticulum stress and 
hyperinsulinemia, contributes to the development of hepatic steatosis, which aggravates of 
insulin resistance (42;45). 
 Collectively, this study identifies ATF3, c-jun, Egr1, MKP1 and SREBP1c as 
insulin-regulated ATF2 target genes. Intriguingly, deregulation of (downstream targets of) 
these genes is highly linked to the pathogenesis of insulin resistance, β-cell dysfunction and 
vascular complications found in type 2 diabetes. Therefore, this study not only substantiates 
a role for ATF2 in insulin action, but also suggests that aberrant ATF2 activation under 
conditions of insulin resistance may contribute to the development of type 2 diabetes. 
 
Materials and methods 
Materials. Tissue culture media were obtained from Invitrogen (Carlsbad, Ca, USA), and 
SP600125 was from Biomol (Plymouth meeting, PA, USA). Antibodies recognizing 
phospho-T71-ATF2 (#9221), phospho-T69/T71-ATF2 (#9225), phospho-T202/Y204-
ERK1/2 (#9101), and phospho-S473-PKB (#9271) were from Cell Signaling Technology 
(Beverly, MA, USA), anti-ATF2 (C19) and anti-insulin receptor β-subunit (C19) were from 
SantaCruz Biotechnology (Santa Cruz, CA, USA). Anti-elongation factor 1β (EF1β) has 
been described (46). 
Generation of shRNA ATF2 constructs. To produce mouse-specific ATF2 shRNA 
constructs, we used the siRNA target finder to select oligonucleotides that were 
subsequently verified for specificity for mouse ATF2 (mATF2) by BLAST analysis of the 
mouse genome database. Sense and antisense versions of two silencing oligonucleotides, 
i.e. 5’-TGAGGAGCCTTCTGTTGTA-3’ (mATF2#1), and 5’-
GTGCCAAGCAGTCCACATA-3’ (mATF2#2), corresponding to nucleotides 727-745 and 
1685-1703, respectively, of the predicted mRNA ATF2 sequence in the mouse genome 
database were inserted into forward (5’-gatccccSENSEttcaagagaANTISENSEtttttggaaa-3’) 
and reverse oligonucleotides (5’-agcttttccaaaaaSENSEtctcttgaaANTISENSEggg-3’) 
purchased from Eurogentec (Liege, Belgium). Oligonucleotide pairs were annealed and 
phosphorylated and ligated into BglII- and HindIII-digested pSuperH1 (47). The pSuper-
shATF2 constructs were verified by restriction and sequence analysis.  
Cell culture and transient transfections. 3T3L1 adipocytes were purchased from the 
American Type Culture Collection (Manassas, VA, USA), and cultured and differentiated 
in adipocytes as described previously (48). A14 cells are NIH3T3 fibroblasts 
overexpressing the human insulin receptor, and grown in DMEM supplemented with 10% 
fetal bovine serum and antibiotics (19). For silencing experiments, A14 cells were 
transfected in 6-well plates with 500 ng of the pSuper ShRNA construct and 125 ng of 
pBabe-puro using Fugene 6 reagent (Roche Biochemicals, Indianapolis, IN). The next day, 
the cells were split into 2 6-well dishes, and selected with 3 µg/ml of puromycin (Sigma 
Aldrich, St. Louis, MO, USA) for 2 days, after which cells were serum-starved overnight 
and stimulated with insulin where indicated. 
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RNA extraction and real-time PCR analysis. Cells were homogenized in RLT-buffer 
(Qiagen, Venlo, The Netherlands), whereafter total RNA was extracted using RNeasy mini 
columns (Qiagen, Venlo, The Netherlands). DNase I digestion was performed to ensure 
complete removal of DNA. Purity and quantity of nucleic acids was determined by 
spectrophotometric analysis at 260 and 280 nm. Integrity of the RNA was verified by 
agarose gel electrophoresis. A total of 1.0 µg RNA was transcribed into complementary 
DNA using a SuperscriptTM first strand synthesis kit (Invitrogen, Breda, The Netherlands) 
using oligo-dT priming. mRNA abundance was measured using real-time PCR. Primers are 
listed in Table 2, and were designed using Primer Express version 3.0 software (Applied 
Biosystems, Foster City, CA, USA).  
 
Table 2. Sequences of primers used for real-time PCR 
Gene name Accession number Forward primer (5’->3’) Reverse primer (5’->3’) 
18S rRNA NR_003278 gactcaacacgggaaacctc agacaaatcgctccaccaac 
adiponectin NM_009605 ggaatgacaggagctgaagg cgaatgggtacattgggaac 
ATF2 NM_001025093 gactccaacgccaacaagat aggtaaagggctgtcctggt 
ATF3 NM_007498       aacacctctgccatc ttatttctttctcgccgcctc 
β-actin NM_007393 agagggaaatcgtgctgac caatagtgatgacctggccgt 
c-jun NM_010591  caacatgctcagggaacaggt tgcgttagcatgagttggca 
CREB1 NM_133828 ggagcttgtaccaccggtaa gggctaatgtggcaatctgt 
EF1α NM_010106 aattggaggcattggcac aaaggtaaccaccatgccagg 
Egr1 NM_007913 aacactttgtggcctgaacc aggcagaggaagacgatgaa 
FABP4 NM_024406 aagaagtgggagtgggcttt ctgtcgtctgcggtgattt 
FOXO3a NM_019740 ttcccatataccgccaagag tgacgcaaggagttcagaga 
HIF1α NM_010431 cctggaaacgagtgaaagga ctgccttgtatgggagcatt 
IGF2 NM_010514 gagttcagagaggccaaacg tagtgtgggacgtgatggaa 
IGFBP6 NM_008344 cagagaccggcagaagaatc ctcggaagacctcagtctgg 
IL1β NM_008361 caggcaggcagtatcactca aggtgctcatgtcctcatcc 
MKP1 NM_013642  ctcatgggagctggtcctta gcgaagaaactgcctcaaac 
PEPCK NM_011044 tctgaggccacagctgctg gggtcgcatggcaaagg 
PGC1α NM_008904 tttttggtgaaattgaggaatgc cggtaggtgatgaaaccatagct 
PPARα NM_011144 caacccgccttttgtcatac cctctgcctctttgtcttcg 
SREBP1c NM_011480 ggagccatggattgcacatt cctgtctcacccccagcata 
TNFα NM_013693 gtccccaaagggatgagaag cacttggtggtttgctacga 
 
Reactions were carried out in the presence of 1x SYBR® Green PCR Master Mix (Applied 
Biosystems), 0.5µM of each forward and reverse primer on a StepOne Plus Real-time PCR 
system (Applied Biosystems) with the following cycle conditions: 95oC for 10 min 
followed by 40 cycles of 95oC for 15”, 60oC for 30”, and 72oC for 30”. The threshold cycle 
number (Ct) was calculated using StepOne Plus software version 2.0 (Applied Biosystems) 
and an automated setting of the baseline. Data were analyzed using a comparative critical 
threshold (Ct) method in which the amount of target is normalized to the amount of 
endogenous control using the equation Ra=2
-∆Ct in which Ra = the relative mRNA 
abundance, and ∆Ct=Ct(gene of interest)-Ct(endogenous control), and Ct(endogenous 
control) is calculated as the geomean(Ct) of FABP4, ATF2, EF1α, and β-actin in 3T3L1 
adipocytes, and geomean(Ct) of 18S rRNA, EF1α, β-actin in A14 fibroblasts, respectively. 
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The expression of the genes used as endogenous control was not affected by the 
experimental conditions used in this study. 
Analysis of insulin signaling. Cells were washed twice with ice-cold PBS and lysed in 30 
mM Tris.Cl, pH 7.5, 150 mM NaCl, 0.5% Triton X-100, 0.5% sodium deoxycholate, 1% 
SDS, 1 mM Na3VO4, 10 mM NaF and protease inhibitors (Complete, Roche). Cell lysates 
were cleared by centrifugation (13.200 rpm; 15 min, 4oC), and protein content was 
determined using a bicinchoninic acid protein assay kit (Pierce, Rockford, IL, USA). 
Expression and phosphorylation of proteins was studied by SDS-PAGE and Western 
blotting as described (5). 
Statistical analysis. Data are expressed as means ± SE. Differences between groups were 
determined by unpaired students two-tailed t-test using SPSS version 16.0. P<0.05 was 
considered statistically significant. 
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Activating transcription factor 2 (ATF2) has been identified as a component of insulin 
signalling in cultured cells. ATF2-activation has been linked to the regulation of 
metabolic enzymes, but also to β-cell apoptosis, inflammation and diabetic 
neuropathy. To detail the function of ATF2 in insulin action, we studied the induction 
of ATF2-phosphorylation and potential ATF2 target genes by insulin in vivo and 
examined the effects of high-fat diet (HFD) induced insulin resistance on these 
parameters in mice. Insulin infusion induced a transient increase in ATF2-
phosphorylation in the liver, white adipose tissue (WAT) and pancreas. In the liver, 
insulin infusion increased the expression of the potential ATF2-target genes ATF3, c-
jun, Egr1, and SREBP1c. In the absence of insulin, basal ATF2 phosphorylation was 
increased in the liver and WAT of HFD-fed mice. This was accompanied by increased 
hepatic mRNA levels of the pro-inflammatory cytokines IL1β and TNFα, in addition 
to ATF3, c-jun, Egr1, and SREBP1c. Furthermore, the livers from HFD-fed mice were 
resistant for the induction of ATF2-target genes by insulin. We conclude that ATF2 
has a dual role in insulin action as it is activated both by insulin infusion and under 
conditions of HFD-induced insulin resistance. The induction of pro-inflammatory 
cytokines in the liver of HFD-fed mice only suggests a state of chronic inflammation, 
which may contribute to the development of type 2 diabetes. 
  
Activating transcription factor 2 (ATF2) is a component of the insulin signaling system. In 
A14 fibroblasts and 3T3L1 adipocytes, insulin rapidly phosphorylates ATF2 on its 
transactivation sites, Thr69 and Thr71 (1;2).  This phosphorylation results in activation of 
the protein and induction of ATF2-target genes, including ATF3, c-jun, Egr1, MKP1 and 
SREBP1c (3). Also other studies indicate a role for ATF2 in metabolic control. In skeletal 
muscle and brown adipose tissue, the p38/ATF2 pathway regulates the expression of 
PPARγ coactivator 1α (PGC1α) (4;5), and of phosphoenolpyruvate carboxykinase 
(PEPCK) in the hepatoma cells (6;7). Finally, studies on the Drosophila fat body, the 
equivalent of the mammalian liver and adipose tissue, identify the p38/ATF2/PEPCK 
pathway as critical regulator of lipid metabolism (8). 
It should be noted, however, that several ATF2-target genes are also highly linked 
to the pathogenesis of insulin resistance, β-cell dysfunction and complications found in type 
2 diabetes. In β-cells, the ATF2-mediated induction of both the pro-inflammatory cytokine 
interleukin 1β (IL1β) and ATF3, in response to nitric oxide, hyperglycemia, high levels of 
palmitate, pro-inflammatory cytokines or endoplasmic reticulum stress, precedes apoptosis 
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(9-11). In endothelial cells, Egr1-regulated genes, like platelet-derived growth factor, 
TNFα, intracellular adhesion molecule-1, monocyte chemotactic protein-1, plasminogen 
activator inhibitor-1, and vascular adhesion molecule-1, have been implicated in the 
development of atherosclerosis (12;13). Finally, uncontrolled activation of SREBP1c has 
been implicated in the development of hepatic steatosis, which aggravates insulin resistance 
(14;15). Interestingly, also the upstream regulator of ATF2, JNK, has been linked to the 
pathogenesis of insulin resistance. Hirosumi et al. found elevated JNK activity in liver, 
adipose tissue and skeletal muscle of obese insulin resistant mice, and knockout of Jnk1 
(Jnk1−/−) or inhibition of JNK-activity restores insulin sensitivity in mouse models of 
insulin resistance (16;17). It has been proposed that JNK phosphorylates the insulin 
receptor substrate 1 on Ser307, thereby inhibiting the insulin-mediated activation of protein 
kinase B, a master regulator of glucose metabolism (18;19).  
The elevated basal activity of JNK, and the involvement of, amongst others, 
ATF3, IL1β, Egr1, and SREBP1c in β-cell apoptosis and insulin resistance, suggests that 
deregulation of ATF2 activity may contribute to the pathogenesis of type 2 diabetes 
mellitus. The present study aimed at detailing the role of ATF2 in insulin action and insulin 
resistance. Therefore, we analyzed the in vivo phosphorylation of ATF2 and the expression 
of ATF2-target in insulin target tissues of mice before and after an insulin infusion. 
Furthermore, we examined whether these responses were altered under conditions of high-
fat diet-induced insulin resistance and obesity. 
 
Results 
Insulin induces ATF2 phosphorylation in vivo. We used male C57/Bl6J mice, fasted 
overnight, to examine ATF2 phosphorylation following an infusion with either PBS or 
insulin. To ascribe alterations in ATF2 phosphorylation levels to insulin rather than changes 
in blood glucose levels, glucose was co-infused to maintain euglycemia. Table 1 lists the 
animal characteristics at sacrifice. Mean body weight was similar among the experimental 
groups. Plasma insulin levels were 77±10 pmol/L in PBS-infused mice and 435±96 pmol/L 
and 467±84 pmol/L following 10 and 20 min of insulin infusion (both P<0.01 versus PBS). 
Blood glucose levels were similar in all groups (Table 1). 
 
Table 1. Characteristics of overnight fasted mice following PBS or insulin infusion 
 PBS 
(n=7) 
10 min INS 
(n=6) 
20 min INS 
(n=7) 
Body weight at sacrifice (gram) 24.2±0.6 23.6±0.7 22.9±0.7 
Fasting blood glucose (mmol/L) 6.2±0.7 5.6±0.6 6.4±0.7 
Glucose at sacrifice (mmol/L) 5.7±0.4 4.7±0.4 4.8±0.4 
Insulin at sacrifice (pmol/L) 77±17 435±96* 467±84* 
Values are mean±SEM, *, P<0.05 versus PBS 
 
Immunohistochemical staining (IHC) with phospho-ATF2-Thr71 antibodies shows a 
nuclear staining throughout the liver and pancreas of insulin-infused mice only (Figure 1). 
Notably, in the pancreas, ATF2-Thr71 phosphorylation tended to be enriched in the insulin-
secreting β-cells (Figure 1). Application of the phospho-ATF2-Thr69+71 antibody failed to 
produce a detectable signal in IHC (data not shown). 
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Figure 1. Immunohistochemical staining of mouse liver and pancreas tissue sections with phospho-ATF2-Thr71 
antibodies (ATF2-P71), or hematoxylin (HE; blue) in combination with insulin (brown). Mice were infused with 
either PBS or insulin for the indicated times. Photographs are representative of 2-3 independent animals. Full- 
colour illustration can be found at page 127. 
  
Instead, we examined the insulin-mediated induction of ATF2-Thr71 and ATF2-Thr69+71 
phosphorylation in homogenates of insulin target tissues. Ten minutes after initiation of the 
insulin infusion, ATF2-Thr71 phosphorylation levels were increased 2.9-fold in liver 
(P<0.05 versus PBS-infusion, Figure 2). At this time point, phosphorylation levels of 
ATF2-Thr69+71 were increased 2.6-fold (P<0.05 versus PBS infusion, Figure 2). Hepatic 
ATF2 was still phosphorylated after 20 min insulin infusion (Figure 2), but had returned to 
basal levels 2 hrs after insulin infusion (data not shown). 
In epididymal adipose tissue, all phospho-ATF2 antibodies detected a band 
migrating at ~64-kDa rather than the 70-kDa band observed in the liver. This protein was 
also detected by an antibody recognizing the aminoterminal part of ATF2 and was 
downregulated upon silencing the ATF2 gene in murine fibroblasts (data not shown). 
Therefore, it is likely that the observed immunoreactivity in adipose tissue results from an 
alternative splice variant of ATF2 (Chapter 2). The immunoreactivity of phospho-ATF2-
Thr71 was increased by 2.3- and 2.5-fold after 10 and 20 min of insulin infusion, 
respectively (P<0.05; Figure 2). In contrast to the liver, ATF2-Thr69+71 phosphorylation 
was not significantly affected by insulin in adipose tissue (Figure 2). 
 Because of the multiple cell types present in the pancreas, we used cultured rat 
INS-1E insulinoma cells to confirm insulin-mediated ATF2 phosphorylation in insulin-
secreting β-cells. Insulin rapidly increased both ATF2-Thr71- and ATF2-Thr69+71-
phosphorylation, with peak levels occurring at 5 min after insulin addition, followed by a 
gradual decrease after 15 and 30 min (Figure 2). The increases in ATF2 phosphorylation by 
western blot could not be ascribed to major changes in ATF2 protein levels (Figure 2).  







In heart and skeletal muscle, we could not detect the induction of ATF2 phosphorylation 
following insulin infusion, despite the presence of ATF2 protein in these tissues (data not 
shown). Activation of insulin signalling in all tissues was confirmed by increased 
phosphorylation of the PKB/Akt substrate PRAS40 (20) in insulin-infused animals (Figure 




Figure 2. A. Phosphorylation of ATF2 and PRAS40, and expression of ATF2 in mouse liver and adipose tissue 
homogenates following infusion with PBS or insulin, and  INS-1E cells, following incubation with 1 µM insulin 
for the indicated amounts of time. Western blots are representative of 7 independent mice per group or 2 
independent experiments and verified for equal loading by PonceauS staining (not shown). B/C. Quantification of 
ATF2 phosphorylation in the liver (B) and adipose tissue (C). The relative ATF2 phosphorylation after PBS 
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Induction of ATF2-target genes by insulin. Using real-time PCR, we examined the 
expression of 10 potential ATF2-target genes, i.e. ATF3, c-jun, Egr1, HIF1α, IL1β, MKP1, 
PEPCK, PGC1α, SREBP1c, TNFα in mouse livers. Livers were isolated from chow-fed 
mice, after an overnight fast or 2 h after initiation of a hyperinsulinemic euglycemic clamp. 
Table 2 shows that the mean body weight was similar between the experimental groups. 
Plasma insulin levels were 136±18 pmol/L in PBS-infused mice and 454±108 pmol/L 
following 2 h hyperinsulinemia. Blood glucose levels were similar between the groups 
(Table 2).  
 As shown in Figure 3, hyperinsulinemia increased the expression of ATF3, c-jun, 
Egr1 and SREBP1c by 1.4-, 1.4-, 2.7- and 3.0 fold (all P<0.05 vs basal), respectively. 
Furthermore, insulin lowered the levels of 4 genes (HIF1α, PEPCK, PGC1α and TNFα) 
and did not affect the abundance of IL1β and MKP1 (Figure 3). 
 
 
Figure 3. Effect of hyperinsulinemia on the expression of ATF2-target genes. Mice, fasted overnight, were 
sacrificed before (basal; open bars) or 2 h after initiation of a hyperinsulinemic euglycemic clamp (INS; black 
bars). Gene expression levels in the liver were determined by real-time PCR. The relative mRNA abundance (Ra) 
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Table 2. Body and plasma characteristics before and after initiation of a hyperinsulinemic 
euglycemic clamp in mice fed a chow or HFD for 6 weeks. 









Body weight at sacrifice (gram) 24.3±0.6 28.1±1.0* 26.1±1.1 30.6±1.3* 
Fasting blood glucose (mmol/L) 4.2±0.4 4.2±0.2 4.6±0.5 4.4±0.2 
Fasting plasma insulin (pmol/L) 136±18 190±42* 139±25 185±31* 
Glucose at sacrifice (mmol/L) 4.2±0.4 4.2±0.2 4.4±0.2 4.2±0.2 
Insulin at sacrifice (pmol/L) 136±18 190±42* 454±108 592±188 
Values are mean±SEM, *, P<0.05 versus chow 
 
 
Insulin resistance increases basal ATF2 phosphorylation in mice. The effects of insulin 
resistance on ATF2-phosphorylation were determined in tissues from high-fat diet (HFD) 
fed mice (21). Table 2 shows that compared to chow fed mice, a 6-wk exposure to a HFD 
induced obesity. Whereas fasting blood glucose levels were not affected by high-fat 
feeding, fasting plasma insulin levels were elevated in HFD-fed mice. We previously 
reported that HFD-feeding blunted the suppression of hepatic glucose production by insulin 




Figure 4. Western blot (A) and quantification (B) ATF2 phosphorylation in the liver and adipose tissue of chow 
(open bars) or high-fat diet fed mice (black bars). Tissue homogenates of were analyzed by immunoblotting with 
antibodies recognizing total ATF2, phospho-ATF2-Thr71 (ATF2-P71) or phospho-ATF2-Thr69+71 (ATF2-
P69+71) antibodies. PonceauS staining confirmed equal loading of the Western blots (not shown). The relative 
ATF2 phosphorylation in chow fed mice was set at 100. Data are expressed as mean±SEM of 4 independent mice 
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In the liver, HFD-feeding induced a 4.9- and 3.6-fold increase in ATF2-Thr71 and ATF2-
Thr69+71 phosphorylation, respectively (Figure 4; P<0.005 and P<0.01 respectively). Also 
in epididymal adipose tissue, phosphorylation levels of ATF2-Thr71 and ATF2-Thr69+71 
were increased in HFD-fed mice by 1.5- (P<0.001) and 1.8-fold (P<0.005), respectively 
(Figure 4). This increase in basal levels of phosphorylated ATF2 could not be ascribed to 
alterations in ATF2 protein expression (Figure 4). 
 
Increased mRNA levels of ATF2-target genes in the liver of HFD-fed mice. We also 
determined whether the elevated levels of phosphorylated ATF2 in livers from HFD-fed 
mice were accompanied by alterations in the expression of potential ATF2-target genes. 
Figure 5A shows that the abundance of ATF3, c-jun, Egr1, IL1β, SREBP1c and TNFα was 
1.7-, 1.8-, 4.0-, 1.7-, 12.8- and 2.1-fold higher, respectively, in livers from HFD- versus 
CH-fed mice (all P<0.05).  
 
 
Figure 5. Effect of high-fat feeding on the expression of ATF2-target genes. A. Gene expression levels determined 
by real-time PCR in livers, isolated after an overnight fast, from mice fed a chow (open bars) or a high-fat diet 
(black bars). The relative mRNA abundance (Ra) in the liver from chow-fed mice was set at 100. Data are 
expressed as mean ± SEM. *, P<0.05 versus basal (n=6-8 mice/group). B. Effect of 2h hyperinsulinemia on the 
expression of ATF2 target genes in chow (open bars) and high-fat diet (black bars) fed mice. The effect of insulin 
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HFD-feeding had no effect on the expression of HIF1α, MKP1, PEPCK and PGC1α 
mRNA (Figure 5A). Except for MKP1, hyperinsulinemia did not significantly alter the 
expression of the examined genes, indicating that HFD-induced insulin resistance also 
affects insulin regulation of the ATF2 signaling pathway (Figure 5B). 
 
Discussion 
In this study, we examined the effects of insulin and HFD-feeding on the phosphorylation 
of the transcription factor ATF2. We show that insulin infusion induced phosphorylation of 
ATF2 on Thr69 and Thr71 in the liver, epididymal adipose tissue and the pancreas, but not 
in cardiac and skeletal muscle. In the liver, insulin increased the expression of the ATF2-
regulated genes ATF3, c-jun, Egr1 and SREBP1c. Compared to chow-fed mice, HFD-
feeding increased ATF2 phosphorylation in liver and adipose tissue. Elevated mRNA-levels 
of the (putative) ATF2-target genes ATF3, c-jun, Egr-1, SREBP1c, but also of the pro-
inflammatory cytokines IL1β and TNFα accompanied these HFD-induced changes in the 
liver. Finally, livers from HFD-fed mice were resistant for the induction of ATF2-target 
genes in response to insulin.  
The present study extends our previous findings (1;2) and identifies ATF2 as a 
component of physiological insulin action in vivo. The study described here was performed 
with insulin concentrations normally achieved following food intake and under euglycemic 
conditions, thereby excluding the possibility that the observed phosphorylation of ATF2 
results from alterations in plasma glucose levels.  
 Strikingly, in the fasted state with low plasma concentrations of insulin, the levels 
of phosphorylated ATF2 were markedly increased in both the liver and epididymal adipose 
tissue from insulin resistant HFD-fed mice. This indicates a role for ATF2 both in insulin 
action and insulin resistance. The predominant kinases regulating ATF2 phosphorylation 
are ERK1/2, p38 and JNK (1;2;22-25). Numerous studies have demonstrated elevated 
activity of predominantly JNK under conditions of insulin resistance (16;17;19;26;27). 
Therefore, the sustained ATF2 phosphorylation in tissues from HFD-fed animals is likely to 
result from elevated JNK-activity. 
 To detail the dual function of ATF2 in insulin action and insulin resistance, the 
expression levels of potential downstream targets of ATF2 were determined in the livers 
from CH- and HFD-fed mice. Four genes that have been linked with ATF2-activation in 
previous reports, i.e. HIF1α (28), PEPCK (6-8), PGC1α (4;5) and MKP1 (28;29), were 
neither induced by hyperinsulinemia in CH-fed mice nor by HFD-feeding. Tissue-specific 
differences in the expression of ATF2 isoforms which affect the composition of ATF2-
containing heterodimers may contribute to the absence of ATF2-regulation of these genes. 
Furthermore, also other insulin- or HFD-induced signaling pathways may be dominant over 
the ATF2-pathway. For example, the PKB/FOXO pathway, which is strongly activated by 
insulin, has been shown to lower the expression of PEPCK (30) and PGC1α (31).  
Intriguingly, both HFD-feeding and hyperinsulinemia in CH-fed mice increased 
the abundance of 4 potential ATF2-regulated transcription factors, i.e. ATF3, c-jun, Egr1 
and SREBP1c mRNA (3;22;28;32). It should be noted, however, that the magnitude of the 
induction caused by HFD-feeding, in particular of Egr1 and SREBP1c and to a lesser extent 
ATF3 and c-jun, is much higher than that caused by hyperinsulinemia in CH-fed mice. 
Furthermore, IL1β and TNFα mRNA levels were increased in the livers of HFD-fed mice 
only. 
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It is unknown whether these changes can be ascribed to the duration of ATF2 
phosphorylation, which is transient in response to insulin and continuous after HFD-
feeding, or to changes in the composition of ATF2-containing dimers. In this respect, it 
should be noted that cJun is not only an important dimer partner of ATF2 (33), but that it is 
also phosphorylated by JNK (22;23). Thus, increases in both the phosphorylation and 
expression of c-jun may affect the activity and formation of cJun/ATF2 heterodimers in 
HFD-fed mice. 
The identification of ATF3, like ATF2, a member of the ATF/CREB family of 
transcription factors (34), as insulin-regulated gene is surprising. Although ATF3 has been 
implicated in the downregulation of PEPCK (35), induction of ATF3 is strongly linked to 
inducers of (endoplasmic reticulum) stress and apoptosis. Elevated levels of ATF3 in β-
cells, caused by exposure to hyperglycemia, IL1β or nitric oxide (36), induce apoptosis via 
repression of the IRS2 gene (37). Furthermore, ATF3 is linked to mitochondrial 
dysfunction in C2C12 cells and negatively regulates the expression of adiponectin in 
3T3L1 adipocytes (38;39).  
Egr1 is linked to the regulation of cell proliferation and differentiation, amongst 
others by the induction of the homeodomain transcription factor pancreas duodenum 
homeobox-1 (PDX1), a key regulator of insulin expression and pancreatic β-cell 
development, function and survival (40). Also insulin signalling itself is critical for β-cell 
proliferation (41). Thus, an impaired induction of Egr1 by insulin may result in a decreased 
ability of the pancreas to compensate for the increased demand for insulin secretion under 
conditions of insulin resistance. Deregulation of Egr1 activity has further been linked to the 
development of atherosclerosis through enhanced expression of Egr1-target genes in 
endothelial cells (12;13) and adipocytes (42;43). 
SREBP1c is a pivotal regulator of glucose and lipid metabolism, amongst others 
by inducing the expression of glucokinase and genes involved in lipogenesis (14;44). Both 
insulin and HFD-feeding are known inducers of SREBP1c in various tissues (45;46). 
However, unregulated activation of SREBP1c in the liver leads to hepatic steatosis, which 
aggravates insulin resistance (16).  
The pathogenesis of type 2 diabetes is closely associated with chronic 
inflammation as illustrated by abnormal pro-inflammatory cytokine production by various 
tissues (47). The selective increases in IL1β and TNFα in the livers of HFD-fed mice only 
support these findings. These pro-inflammatory cytokines are not only target of ATF2, but 
also potent inducers of ATF2 activation. A limitation of this study is that we could not 
determine the plasma levels of IL1β and TNFα. However, it seems plausible that increases 
in circulating levels of pro-inflammatory cytokines may underlie the increased 
phosphorylation of ATF2 in the liver and WAT of HFD-fed mice, as has been observed by 
others (27;47). 
Although the use of animal models can provide valuable information on 
deregulation of ATF2 under conditions of insulin resistance when compared to cultured cell 
lines, a major limitation is that we cannot formally ascribe the observed changes in gene 
expression to increases in ATF2 phosphorylation. Furthermore, we cannot exclude that the 
increased expression of IL1β and TNFα in HFD-fed mice results from Kupffer cells or 
infiltrated macrophages (27;47). To resolve these issues, studies on mice with tissue-
specific ablation of the ATF2 gene are required. 
We conclude that we have identified ATF2 as a component of the insulin 
signalling system in the liver, pancreas and WAT. However, we also show that ATF2-
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activity is elevated in the liver and WAT of HFD-fed mice, which may contribute to the 
development of type 2 diabetes. This dual role of ATF2 suggests that regulation of ATF2 
activity plays a critical role in insulin action and insulin resistance. 
 
Materials and methods 
Animals. The investigation conformed to the Guide for the Care and Use of Laboratory 
Animals as published by the NIH (NIH Publication No. 85-23, revised 1996) and the 
regulations of the Institutional Animal Care and Use Committee.  
The effects of insulin infusion on ATF2-phosphorylation were studied in adult 
male C57Bl6J mice. Overnight fasted mice were anaesthetized by intraperitoneal injection 
with a combination of 6.25 mg/kg body weight (BW) acetylpromazine (Sanofi Santé 
Nutrition Animale, Libourne Cedex, France), 6.25 mg/kg BW midazolam (Roche, 
Mijdrecht, Netherlands) and 0.3125 mg/kg BW fentanyl (Janssen-Cilag, Tilburg, 
Netherlands). Insulin was infused through the tail-vein at 24.5 pmol/kg BW/min as 
described (48). Glucose was co-infused with insulin at 105 µmol/min to maintain 
euglycemia. At 10 and 20 min following initiation of the insulin infusion, mice were 
sacrificed by cervical dislocation. Control animals were sacrificed following infusion with 
PBS. After sacrifice, organs were removed and either immersion-fixed in 4% buffered 
formaldehyde solution, or snap-frozen in liquid nitrogen and stored at –80oC until further 
use. The effects of insulin resistance were examined in high-fat diet fat mice. Male 
C57Bl6/J mice were randomly divided in two groups and fed either standard lab chow or a 
high-fat diet (HFD). After 6 weeks on the diet, mice were sacrificed following infusion 
with PBS or 2-hrs after initiation of a hyperinsulinemic euglycemic clamp (insulin infusion 
rate: 24.5 pmol/kg BW/min) as described (21). Then, tissues were removed, snap-frozen in 
liquid nitrogen and stored at -80oC until further use. 
Diets. High-fat diet was obtained from Arie Blok Diervoeding (Woerden, The Netherlands, 
cat#4031.05) and consisted (in % of total energy) of 44% bovine fat, 19% protein and 37% 
carbohydrate. Chow diet consisted of 32% proteins, 54% carbohydrates and 14% crude fat. 
Both diets were supplemented with vitamins and microelements.  
Plasma determinations. Blood glucose was measured using a FreeStyle hand glucometer 
(Therasense, Disetronic Medical Systems, Vianen, Netherlands). Plasma insulin levels were 
determined using ELISA (Ultrasensitive mouse insulin kit, Mercodia AB, Uppsala, 
Sweden). 
Cell culture. Ins-1E insulinoma cells (49) were kindly provided by Dr. C. Wollheim 
(University Medical Center, Geneva, Switzerland) and cultured in RPMI 1640 
supplemented with 9% fetal bovine serum (FBS), 25 mM HEPES, glutamax, 1 mM sodium 
pyruvate and antibiotics. 
Immunohistochemistry. Fixed tissues were prepared by routine paraffin embedding, 
sections were cut and mounted on slides. Sections were deparaffinized and washed with 
water for 5 min. Antigen retrieval was performed for ATF2 by boiling in 10 mM citrate 
buffer at pH 6 for 10 min followed by cooling for 20 min. Sections were washed three 
times for 5 minutes with water and endogenous peroxidase activity was blocked in 1% 
H2O2 for 20 min. After washing in water and PBS, sections were preincubated with 5% 
normal goat serum in PBS for 1 h. Incubation with ATF2-phospho-Thr71 antibodies 
(#9221; Cell Signaling Technology, Beverly, MA, USA) (1:50) was overnight at 4°C (50). 
Sections were then washed with PBS, incubated with rabbit Envision-HRP for 30 min, 
washed again and developed using DAB with 0.7% NiCl2 for 10 min (black/blue 
precipitate). Separate sections were counterstained with hematoxylin (blue) or in case of the 
ATF2-phosphorylation in vivo 
 97 
pancreas with insulin (brown) and hematoxylin (blue) (51). Therefore, sections were 
incubated with 1% H2O2, washed and incubated overnight with the insulin-antibody (Dako, 
Glostrup, Denmark) (1:200) at room temperature, followed by washing with PBS, 
incubation with rabbit Envision-HRP for 30 min, washing and developing using DAB for 
10 min. Sections were inspected using a Leica DM-LB light microscope (Leica, Rijswijk, 
The Netherlands) and digital images were captured using a Leica DC500 digital camera and 
software. 
Western blotting. Cell- and tissue homogenates were prepared in 30 mM Tris.Cl, pH 7.5, 
150 mM NaCl, 0.5% Triton X-100, 0.5% sodium deoxycholate, 1% SDS, 1 mM Na3VO4, 
10 mM NaF and protease inhibitors (Complete, Roche) and cleared by centrifugation 
(13.200 rpm; 15 min, 4oC). Protein content was determined using a BCA protein assay kit 
(Pierce, Rockford, IL, USA). Expression and phosphorylation of proteins was determined 
by SDS-PAGE and immunoblotting (2). The antibodies used were: anti-phospho-Thr71-
ATF2 (#9221), anti-phospho-Thr69+71-ATF2 (#9225) (both from Cell Signaling 
Technology, Beverly, MA, USA), anti-ATF2 (C19) (Santa Cruz Biotechnology, Inc., Santa 
Cruz, CA, USA) and anti-phospho-PRAS40-Thr246 (#44-100G) (Biosource International, 
Camarillo, CA, USA). PonceauS staining of the membranes confirmed correct protein 
transfer and equal loading. Bound antibodies were visualized by enhanced 
chemiluminescence. Immunoblots were quantified by densitometric analysis of the films 
(52). 
RNA extraction and real-time PCR analysis. Frozen tissue biopsies (~30 mg) were 
homogenized in RLT-buffer (Qiagen, Venlo, The Netherlands), whereafter total RNA was 
extracted using RNeasy mini columns (Qiagen, Venlo, The Netherlands). DNase I digestion 
was performed to ensure complete removal of DNA. Purity and quantity of nucleic acids 
was determined by spectrophotometric analysis at 260 and 280 nm. Integrity of the RNA 
was verified by agarose gel electrophoresis. A total of 1.0 µg RNA was transcribed into 
complementary DNA using a SuperscriptTM first strand synthesis kit (Invitrogen, Breda, 
The Netherlands) using oligo-dT priming. mRNA abundance was measured using real-time 
PCR. Primers are listed in Table 3 and were designed using Primer Express version 3.0 
software (Applied Biosystems, Foster City, CA, USA). Reactions were carried out in the 
presence of 1x SYBR® Green PCR Master Mix (Applied Biosystems), 0.5µM of each 
forward and reverse primer on a ABI PRISM® 7900HT Sequence Detection System 
(Applied Biosystems) with the following cycle conditions: 95oC for 10 min followed by 40 
cycles of 95oC for 15”, 60oC for 30” and 72oC for 30”. The threshold cycle number (Ct) was 
calculated using SDS software version 2.2 (Applied Biosystems) and an automated setting 
of the baseline. Data were analyzed using a comparative critical threshold (Ct) method in 
which the amount of target is normalized to the amount of endogenous control using the 
equation Ra=2
-∆Ct in which Ra = the relative mRNA abundance and ∆Ct=Ct(gene of 
interest)-Ct(endogenous control) and Ct(endogenous control) is calculated as the 
geomean(Ct) of β-actin and EF1α. The expression of these genes was not affected by the 
experimental conditions used in this study. 
Statistical analysis. Data are expressed as means ± SE. Differences between groups were 
determined by unpaired students two-tailed t-test using SPSS version 16.0. P<0.05 was 




Table 3. Sequences of primers used for real-time PCR 
Gene name Accession number Forward primer (5’->3’) Reverse primer (5’->3’) 
ATF2 NM_001025093 gactccaacgccaacaagat aggtaaagggctgtcctggt 
ATF3 NM_007498       aacacctctgccatc ttatttctttctcgccgcctc 
β-actin NM_007393 agagggaaatcgtgctgac caatagtgatgacctggccgt 
c-jun NM_010591  caacatgctcagggaacaggt tgcgttagcatgagttggca 
EF1α NM_010106 aattggaggcattggcac aaaggtaaccaccatgccagg 
Egr1 NM_007913 aacactttgtggcctgaacc aggcagaggaagacgatgaa 
IL1β NM_008361 caggcaggcagtatcactca aggtgctcatgtcctcatcc 
MKP1 NM_013642  ctcatgggagctggtcctta gcgaagaaactgcctcaaac 
PEPCK NM_011044 tctgaggccacagctgctg gggtcgcatggcaaagg 
PGC1α NM_008904 tttttggtgaaattgaggaatgc cggtaggtgatgaaaccatagct 
SREBP1c NM_011480 ggagccatggattgcacatt cctgtctcacccccagcata 
TNFα NM_013693 gtccccaaagggatgagaag cacttggtggtttgctacga 
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Chapter 7  
 
Summary and Discussion  
 
Insulin elicits complex responses in peripheral tissues like skeletal muscle, adipose tissue, 
the heart, the liver and brain to maintain glucose and lipid homeostasis. Insulin resistance 
and type 2 diabetes are associated with impaired insulin action in these target tissues. In 
order to understand the molecular mechanisms underlying insulin resistance and to develop 
novel (therapeutic) strategies to improve peripheral insulin sensitivity, it is crucial to 
understand the complex responses that are induced by insulin in its target tissues. Insulin 
action is initiated by binding of insulin to its receptor and eventually leads to activation of 
two major effector pathways: the PI-3K-dependent PKB/Akt-pathway and the Ras-
dependent MAPK-pathway. Activation of the PKB/Akt pathway has been linked to the 
regulation of lipid and glucose metabolism, gene expression and cell survival. The MAPK-
pathway contributes to activation of gene expression and cell proliferation. In contrast to 
the PKB/Akt-pathway, the role of the Ras/MAPK in physiological insulin action is less 
well defined. 
 We have identified the transcription factor activating transcription factor 2 (ATF2) 
as a downstream target of the Ras/MAPK signaling pathway and novel component of 
insulin signaling (1). In the research described in this thesis we have further characterized 
the role of ATF2 in insulin action by (i) detailing the mechanism of insulin-induced ATF2 
phosphorylation, (ii) identifying genes whose expression depends on ATF2 and (iii) 
investigating whether the induction of ATF2-phosphorylation and ATF2-regulated genes is 
altered under conditions of insulin resistance. 
Chapters 3 and 4 address the mechanism of ATF2-activation in response to 
insulin. The data reported in these chapters extend the previous findings by further detailing 
the mechanism with which insulin induces ATF2-phosphorylation in the genetic absence 
and presence of JNK. Where stresses seem to induce activation of ATF2 via simultaneous 
phosphorylation of the transactivating residues Thr69+71 dependent on one kinase, insulin 
(and mitogens in general) utilizes a Ras-dependent two-step mechanism employing two 
kinases to achieve this. The data presented in chapters 3 and 4 suggest the following model 
for the induction of ATF2-Thr69+71 phosphorylation in response to insulin in cultured 
cells (summarized in Figure 1): in both JNK-deficient and JNK-containing cells, insulin 
induces early activation of the ERK1/2 via the Ras-Raf-pathway. Active ERK1/2 then 
translocates to the nucleus and mediates ATF2-Thr71-phosphorylation. Minutes later, after 
Ras-RalGDS-Ral dependent activation of p38/JNK, nuclear translocation of active p38 (in 
JNK-deficient cells) or active JNK (in JNK-expressing cells) is responsible for the 
activation of ATF2 by phosphorylation of Thr71-phosphorylated ATF2 on Thr69. We 
propose that, in both JNK-/- and JNK-expressing cells, the difference between the nuclear 
appearance of ERK1/2 and the ATF2-Thr69-phosphorylating SAPK (p38 or JNK) is rate 
limiting for the two-step phosphorylation of ATF2-Thr69+71 in response to insulin. 
Importantly, the data described in chapter 6 confirmed insulin-induced ATF2- 
phosphorylation in several mouse tissues in vivo. However, the question whether in vivo 
ATF2-phosphorylation is also regulated via a two-step mechanism dependent on two 
cooperating kinases remains unanswered. No evidence was found to support a two-step 
process, but as hepatic ATF2 was already found to be phosphorylated on both Thr69+71 at 
the earliest time-point examined (10 minutes after start of insulin infusion), analysis of 
earlier time-points may potentially reveal differential kinetics in phosphorylation of the 
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different ATF2 sites and/or correlating differences in MAPK-activation in response to 
insulin. Experimental procedures to measure in vivo ATF2 phosphorylation at these early 
time points are however difficult to perform.  In adipose tissue and liver, we observed a 
weak and transient induction of p38 and ERK1/2 phosphorylation at the time-points 
examined. Although phosphorylation of JNK could not be detected on western blots, due to 
the presence of interfering background bands and a poor signal-to-noise-ratio, 
pharmacological inhibition of JNK (using SP600125), and not of p38 (with SB203580) 
severely reduced only the ATF2-Thr69 in vitro kinase activity, and not the ATF2-Thr71 
directed activity present in lysates from insulin-treated mouse livers (BB/DMO, 
unpublished results). These preliminary data suggest a potential role for JNK in the in vivo 
Thr69-phosphorylation of ATF2 induced by insulin. Further experimentation, using cell-
permeable inhibitors of JNK that have been described to be functional in whole animals 
(2;3) or JNK-knockout mice (4) can potentially be used to substantiate the involvement of 
JNK in the insulin-induced in vivo ATF2-phosphorylation. Alternatively, the in vivo 
regulation of ATF2-phosphorylation may differ from the mechanism found in cells, and 
other kinases can be involved in this process in vivo. For a more general identification of 
ATF2-kinases activated by insulin in vivo, anion-exchange chromatography of insulin-
treated tissue lysates in combination with ATF2-directed kinase assays can be employed 
(1;5). 
 
Figure 1. Proposed model for insulin-induced ATF2 activation in cultured cells. First, insulin induces Ras-
dependent activation of ERK1/2. ERK1/2 subsequently translocates to the nucleus, where it mediates ATF2-Thr71 
phosphorylation. Subsequently, JNK or (in JNK-deficient cells) p38 is activated. JNK (or p38) then translocates to 
the nucleus, and efficiently phosphorylates Thr71-phosphorylated ATF2 on Thr69, thus inducing transcriptional 
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To begin to detail the role of ATF2 in insulin action, we identified ATF2 target genes in 
insulin-sensitive cell lines and determined their hepatic expression levels in response to 
insulin-stimulation in vivo. In chapter 2, an overview is given on the potential role of ATF2 
and ATF2-regulated genes in metabolic control and/or insulin action. Chapter 5 describes 
the identification of ATF3, c-jun, Egr1, MKP1 and SREBP1c as insulin-induced genes, 
whose expression is ATF2-dependent in both A14 fibroblasts and 3T3L1-adipocytes. 
Although in vivo insulin-inducibility could also be established for most of the identified 
ATF2-dependent genes in mouse liver (ATF3, c-jun, Egr1, and SREBP1c), a role for ATF2 
therein was not formally proven (chapter 6). To obtain such evidence, adenovirus-mediated 
knockdown of hepatic ATF2 and/or Chromatin Immuno Precipitation (ChIP) studies for 
(phosphorylated) ATF2 (which is also possible in other tissues than liver) could be 
performed. Unfortunately, the ATF2 knockout mice or the phospho-dead ATF2AA 
expressing knock-in mice can not be used in studies on insulin action in adult animals, as 
they die shortly after birth (6;7). However, ATF2m/m mice, that express a mutant ATF2-
isoform at low levels (7-9), have been employed to identify ATF2-dependent gene 
transcription and could therefore be suitable in further detailing the function of ATF2 in 
physiological insulin action. Other mouse-models include tissue-specific ATF2-knockout 
mice, which are currently being generated (10), or tissue-specific (inducible) expression of 
dominant negative forms of ATF2. Combination of these experimental setups with large-
scale gene expression-profiling methods, such as microarray or solexa sequencing, could 
produce a higher yield of potential candidates and can provide more insight in the role of 
ATF2 in insulin-induced gene expression. 
 For some of the examined genes that were previously described as ATF2 targets, 
we could not establish ATF2-dependency in either one or both of our cell- or mouse-based 
studies. For example, we could not find any correlation between in vivo ATF2-
phosphorylation and MKP1 expression in mouse livers, despite the fact that MKP1 
expression was found to be ATF2-dependent in cultured cells stimulated with insulin 
(chapter 5) and expression of a number of MKPs (including MKP1) was reported to be 
dependent on intact ATF2-phosphorylation in embryonic livers (6). Apparently, other, 
potentially ATF2-independent, regulatory mechanisms govern the in vivo MKP1 expression 
in the adult animal.  
Some of the other described ATF2-regulated genes (PEPCK, PGC1α, IL1β and 
TNFα) did not show any ATF2-dependency in response to insulin in cultured cells. In 
addition, in vivo insulin-treatment either lowered or had no effect on the expression of these 
genes in liver. For the cytokines IL1β and TNFα, it is not unthinkable that they are not 
expressed in the cell- or tissue-types and/or experimental conditions discussed here (see 
also below).  
Several explanations can be given for the absence of regulation of the described 
ATF2 targets MKP1, PEPCK and PGC1α expression by insulin, both independent of and 
dependent on ATF2. Stimulus- and tissue-specific responses can underlie the apparent 
ATF2-independent regulation of these genes by insulin. The expression of most genes is 
regulated by a high number of factors and depending on the stimulus and cell- or tissue-
type, other signaling pathways may be dominant over the ATF2-pathway. For example, the 
PKB/FOXO pathway, which is strongly activated by insulin in liver, could be crucial in the 
regulation of insulin-induced PGC1α expression (11).  
Alternatively, expression of different ATF2-isoforms and/or ATF2-binding 
partners, some of which have been reported to repress transcription (e.g. ATF2d (12) and 
ATF3 (13)), can have opposing effects on ATF2-dependent gene regulation. Our 
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unpublished results suggest that several ATF2-isoforms are (co-)expressed in a tissue-
specific manner (see figure 2). Differences in promoter-, co-factor- or dimer partner-
specific characteristics would then determine which isoform of the ATF2 protein would be 
dominant in regulating a specific gene. 
 
Figure 2. Expression of ATF2 isoforms in target tissues for insulin action. Lysates from mouse liver, adipose 
tissue, skeletal and cardiac muscle were analyzed by Western blotting using antibodies recognizing the first 96 (N) 
or last 19 (C) amino acids of ATF2. 
 
A still unanswered question is how the identified ATF2-target genes impact on 
insulin action and metabolic control. Most of the positively identified insulin-induced 
ATF2-dependent genes encode transcription factors (e.g. Egr1, ATF3, c-jun and 
SREBP1c), whose targets have been postulated to be involved in several aspects of normal 
insulin action, like proliferation and differentiation of β-cells (for Egr1 and cJun (14-16)), 
control of hepatic fat and glucose metabolism (SREBP1, ATF3, cJun and Egr1 (13;17-19)).  
Further studies in relevant physiological models could be used to address their role in 
normal insulin action. One can think of ectopic expression of these factors in ATF2-
‘deficient’ models (ATF2m/m mice (9) or (virus-mediated) knockdown of ATF2 in cellular 
model systems or in mouse liver), but not after a role for ATF2 in the regulation of these 
genes is established more firmly. 
Finally, deregulation of a number of (potential) ATF2-target genes described in 
chapters 2 and 5 has also been associated with pathogenesis of insulin resistance, e.g. β-cell 
dysfunction and vascular complications found in type 2 diabetes (see chapter 2 for 
references). In addition, cytokine- or ER-stress-induced activation of one of the major 
ATF2 kinases: JNK, has been described to play a role in the development of insulin 
resistance in a number of tissues (reviewed in (20-22)). This suggests that next to a role in 
normal insulin action, ATF2 and its target genes could also be involved in the development 
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To assess if insulin-resistance impacted on ATF2-phosphorylation, we examined ATF2-
phosphorylation and expression of ATF2-dependent genes in tissues of high fat diet (HFD)-
induced insulin-resistant mice. We found that already in the fasting state with low plasma 
concentrations of insulin, HFD induced increased ATF2-phosphorylation in livers and 
adipose tissue of insulin-resistant mice (chapter 6). As numerous studies have described 
elevated JNK-activity in HFD-induced insulin resistant states (4;23), the increased ATF2 
phosphorylation found here, is probably (at least partially) mediated by JNK. 
Correlating with the increased ATF2-phosphorylation found in these mice, HFD 
induced basal hepatic expression of the ATF2-dependent genes identified in chapter 5: 
ATF3, c-jun, Egr1 and SREBP1c. The described ATF2 target genes IL1-β and TNFα  were 
also significantly induced by the HFD in liver, presumably produced by hepatic Kupfer 
cells or infiltrated macrophages activated by the HFD-induced state of chronic 
inflammation. The insulin-induced enhancement of all of these genes was severely reduced 
in the HFD-fed animals, correlating with the inability of insulin-administration to further 
increase ATF2 phosphorylation. 
  To ascertain the ATF2-involvement in this process, similar experiments as 
suggested above could be performed, e.g. comparison of (phospho-)ATF2-ChIPs in chow 
vs HFD-fed mouse tissues and/or analysis of the development of HFD-induced insulin-
resistance in ATF2m/m mice or in mice with tissue-specific inactivation of ATF2 (10). 
Notably, as ATF2 is highly expressed in the brain (24;25) and there is increasing evidence 
for metabolic control via the brain (25-29), potential regulation of metabolism via central 
(neuronal) ATF2 should be considered. To further define the potential role of ATF2 in 
JNK-dependent HFD-induced insulin resistance analysis of the ATF2-phosphorylation 
status and ATF2-dependent gene expression in JNK-knockout mice (4;23;30;31) and/or 
combination of ATF2- and JNK-deficient mouse models could also be useful. 
As a number of other genes related to metabolic control (such as PEPCK (32;33)) 
or the development of diabetes and/or its associated complications (for example the pro-
inflammatory cytokine TNFα (9)) have been shown to be ATF2-dependent in several 
different experimental settings (see chapter 2), including these genes as targets in ChIP–on-
chip experiments or larger scale expression profiling in several of the models described 
above could be particularly interesting. 
 In conclusion, we have identified ATF2 as a component of the cellular and in vivo 
insulin signaling systems. Insulin induced ATF2-phosphorylation in A14 fibroblasts, 
3T3L1 adipocytes and several mouse tissues in vivo. In cell lines, the insulin-induced 
ATF2-phosphorylation was dependent on cooperation between two Ras-dependent MAPK-
pathways: ERK and p38/JNK. Analysis of several described ATF2-target genes identified 
insulin-induced expression of Egr1, ATF3, c-jun and SREBP1c as being ATF2-dependent 
in cell lines. Quantitative PCR analysis showed increased mRNA expression of these genes 
in mouse livers correlating with hepatic ATF2-phosphorylation induced by insulin, but also 
in response to HFD-induced insulin resistance. Although the elucidation of the exact role of 
ATF2 activation under these conditions needs further experimentation, the data presented in 
this thesis suggest a potential dual function for ATF2 as a mediator of insulin action on the 
one hand and a putative regulator of the development or maintenance of insulin resistance 
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Insulin induceert complexe responsen in perifere weefsel zoals de skeletspier, vet, hart, 
lever en het brein om glucose- en vet-homeostase te bewerkstelligen. Een verminderde 
insulinewerking met betrekking tot de glucose-huishouding in deze organen wordt insuline 
resistentie genoemd en is een kenmerk van type 2 diabetes. Teneinde op een moleculair 
niveau de mechanismen te begrijpen welke ten grondslag liggen aan insuline resistentie en 
nieuwe strategieën te ontwikkelen om de insuline resistentie te verminderen is beter inzicht 
in het moleculaire mechanisme van de cellulaire insuline-respons vereist. Binding van 
insuline aan zijn receptor leidt tot activatie van twee intracellulaire signaal-transductie 
routes: een PI-3K-afhankelijke PKB/Akt route en een Src/Ras-afhankelijke MAPK route. 
Activatie van de PKB/Akt route is vooral belangrijk voor de acute regulatie van het vet- en 
glucose-metabolisme. Tevens reguleert deze route tevens gen-expressie en cel-overleving. 
De MAPK-route lijkt vooral belangrijk voor activatie van gen-expressie en cellulaire 
proliferatie. In tegenstelling tot de PKB/Akt-route, is er nog weinig bekend over de rol van 
de Ras/MAPK-route bij de fysiologische insuline werking. 
  
In onze onderzoeksgroep is de transcriptie factor ATF2 geïdentificeerd als een van de 
componenten van de Ras/MAPK signaalroute en tevens als nieuw onderdeel van  de 
insuline signaal-transductieketen. In dit proefschrift hebben we de rol van ATF2 in de 
insuline-geïnduceerde respons verder onderzocht. Het onderzoek beschreven in dit 
proefschrift valt in de volgende drie deelvragen uiteen:  
 
1. Wat is het mechanisme van insuline-geïnduceerde ATF2-fosforylering?  
2. Welke insuline-gereguleerde genen zijn ATF2-afhankelijk?  
3. Is de regulatie van ATF2-fosforylering en ATF2-afhankelijke genen veranderd in een  
 situatie van insuline resistentie? 
 
In de hoofstukken 3 en 4 wordt het onderzoek naar het mechanisme van de insuline-
geïnduceerde fosforylatie van ATF2 beschreven. De hierbij verkregen resultaten  sluiten 
aan bij de eerder gepubliceerde bevindingen (zie Ouwens et al. EMBO J 2002). In 
tegenstelling tot stress-stimuli, die een min of meer gelijktijdige fosforylering van ATF2 op 
de Threonine (Thr)69 en Thr71 induceren - een reactie die vermoedelijk uitgevoerd wordt 
door één kinase - induceren insuline en verwante groeifactoren ATF2-fosforylering op 
Thr69 en Thr71 via een Ras-afhankelijk twee-staps mechanisme waarin twee MAPK-routes 
samenwerken. Op basis van de resultaten beschreven in hoofdstuk 3 en 4 lijkt het volgende 
mechanisme voor insuline-geïnduceerde ATF2-fosforylering waarschijnlijk: Insuline 
activeert het MAPK ERK1/2, via activatering van de Ras-Raf-route. Actief Erk1/2 beweegt 
naar de kern waar het ATF2 fosforyleert op aminozuur Thr71. Minuten later, na een Ras-
Ral-afhankelijke activatering van de stress-kinases p38 en/of JNK, migreren deze kinases 
naar de kern waar ze Thr71-gefosforyleerd ATF2 opnieuw fosforyleren, nu op Thr69.  Door 
gebruik te maken van cellen die specifiek JNK missen, hebben we tevens aangetoond dat 
het kinase p38 op zich al in staat is om deze fosforylering te bewerkstelligen. In JNK-
bevattende cellen lijkt echter het grootste deel van de Thr69-fosforylering via JNK te 
verlopen. De verkregen resultaten suggereren dat samenwerking tussen deze routes 
noodzakelijk is en dat het verschil in de migratiesnelheid tussen actief ERK1/2 en 
respectievelijk JNK/p38 verantwoordelijk is voor de twee-staps fosforylering van ATF2 in 




In hoofdstuk 6 beschrijven we dat deze situatie van ATF2 fosforylering zich ook voordoet 
in levende dieren. In een muizen-model kon worden bevestigd dat infusie van insuline in 
vivo tot ATF2-fosforylering in lever, vet-weefsel en de pancreatische β-cel leidt. Of dit 
proces in de muis via precies dezelfde stappen verloopt als bij de gekweekte cellen, konden 
we vanwege technische redenen niet in detail vaststellen. 
In hoofdstuk 2 wordt op basis van literatuuronderzoek bediscussieerd welke rol 
ATF2 en ATF2-gereguleerde genen potentieel zouden kunnen spelen bij metabole regulatie 
en de insuline respons in het bijzonder. Om een begin te maken de fysiologische rol van 
ATF2 in insuline actie te begrijpen, is van een aantal van deze insuline-gereguleerde genen 
de ATF2-afhankelijkheid onderzocht in insuline-gevoelige cellijnen (hoofdstuk 5). 
Vervolgens hebben we in een in vivo situatie onderzocht in hoeverre de expressie van deze 
genen in de lever, in vivo, onder controle van insuline staat (hoofdstuk 6). Met behulp van 
farmacologische remming van ATF2-activatie en via ATF2-knockdown experimenten werd 
in A14 fibroblasten en 3T3L1-adipocyten aangetoond dat voor efficiënte insuline-
geïnduceerde expressie van een aantal genen (ATF3, c-jun, Egr1, MKP1 en SREBP1c ) 
ATF2-activatie, dan wel expressie van ATF2 cruciaal is (hoofdstuk 5). Hoewel de meeste 
van deze ATF2-afhankelijke genen (ATF3, c-jun, Egr1 en SREBP1c) ook in vivo door 
insuline in muizen-levers werden geïnduceerd (hoofdstuk 6), hebben we hierbij de 
betrokkenheid van ATF2 niet kunnen onderbouwen. 
 Een aantal van de (potentieel) ATF2-afhankelijke genen beschreven in hoofdstuk 
2 en 5 is betrokken bij de pathogenese van insuline resistentie/type 2 diabetes. Bovendien 
draagt hyperactivatie van de het ATF2-kinase JNK ook sterk bij aan dit proces. Op basis 
van bovenstaande gegevens lijkt er in de ontwikkeling van insuline resistentie/type 2 
diabetes een rol voor ATF2 te zijn weggelegd. Om die reden hebben we in hoofdstuk 6 ook 
gekeken naar de staat van ATF2-fosforylering en (insuline-geïnduceerde) expressie van 
ATF2-gereguleerde genen in een in vivo insuline resistente situatie. Daarvoor zijn muizen 
resistent voor insuline gemaakt door ze een aantal weken een ‘hoog-vet’ dieet (HVD) te 
voeren. Ten opzichte van de controle dieren werd er in de lever en het vetweefsel van 
insuline resistente muizen een significante verhoging van ATF2-fosforylering gevonden. In 
de levers van de HVD-muizen ging de basaal verhoogde ATF2-fosforylering gepaard met 
een verhoogde expressie van de in hoofdstuk 5 beschreven ATF2-afhankelijke genen. In 
tegenstelling tot de controle dieren had insuline-infusie geen additioneel inducerend effect 
meer op de hepatische expressie van deze ATF2-target genen. Bovendien was de expressie 
van eerder beschreven ATF2-target genen betrokken bij de immuun respons (IL1β en 
TNFα) ook verhoogd in de HVD-situatie.  
 Samenvattend kan gesteld worden dat het hier beschreven onderzoek ATF2 heeft 
geïdentificeerd als component van de insuline signaal-transductie route, zowel in vitro als 
in vivo. In cellijnen werd de insuline-geïnduceerde ATF2-fosforylering gemedieerd door 
samenwerking van twee Ras-afhankelijke MAPK-routes: ERK en p38/JNK. Het lijkt 
waarschijnlijk dat een soortgelijk mechanisme in vivo plaatsvindt. 
 Door analyse van beschreven ATF2-target genen in cellijnen hebben we laten zien 
dat de insuline-geïnduceerde expressie van Egr1, ATF3, c-jun en SREBP1c afhankelijk is 
van  ATF2. Het bleek dat het in vivo expressie niveau van deze genen correleerde met een 
verhoogde ATF2-fosforylering in respons op insuline enerzijds, maar anderzijds ook in 
response op HVD-geïnduceerde insuline resistentie. Opmerkelijk is dat een hoog vet dieet 
insuline resistentie induceert en een verdere fosforylering van ATF2 door insuline 
verhindert. Ondanks het feit dat het ophelderen van de precieze rol van ATF2 fosforylering 
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in deze situaties nader onderzoek vereist, suggereren de hier beschreven data dat ATF2 
mogelijk een duale rol speelt: enerzijds als een mediator van normale insuline werking, 
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Figure 3. Serum-induced ATF2-Thr69+71, but not Thr71-phosphorylation is SB203580-sensitive in JNK-/- 
cells. Serum-starved JNK-/- cells were treated with SB203580 (SB) for 30 minutes prior to stimulation with 20% 
serum (FCS) for 8 minutes. Cells were fixed and stained with antibodies for (A) Thr71- or (B) Thr69+71-





























Figure 5. The onset of ATF2-Thr71 and ATF2-Thr69+71-phosphorylation associates with nuclear translocation 
ERK1/21/2 and p38. (A) Serum-starved JNK-/- cells were stimulated with 20% serum (FCS) and fixed at the times 
indicated. The fixed cells were stained with antibodies for phospho-ERK1/2 (ERK1/2-PP) or phospho-p38 (p38-
PP) followed by FITC-conjugated secondary antibodies (green). DNA was stained with DAPI (blue). (B) Serum-
starved JNK-/- cells pre-treated with vehicle or SB203850 for 30 minutes prior to 8 minute FCS-stimulation were 
fixed and stained for phospho-p38 (p38-PP) as described above. (C) Serum-starved JNK-/- cells, pre-treated with 
vehicle or SB203850 were serum-stimulated for 8 minutes, after which cellular fractions were prepared and the 
nuclear fractions examined for p38- and ATF2-Thr69+71 phosphorylation by immunoblotting with phospho-
specific antibodies as described.  
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Figure 3. Early insulin-induced ATF2-Thr71 phosphorylation is sensitive to inhibition of the MEK1/2-ERK1/2 
pathway. Serum-starved A14 cells (A) or 3T3L1 adipocytes (B) were incubated with 10 µM U0126 (U; 15 
minutes) or 2.5 µM SB203580 (SB; 30 minutes) before insulin-stimulation (INS; 10 nM) for 4 minutes. Total 
ATF2 and ATF2-Thr71-phosphorylation levels were determined by immunoblotting with specific antibodies. (C) 
A14 cells were treated with inhibitors as described above, prior to stimulation with 10 nM of insulin for 4 minutes. 
Subsequently, cells were fixed and stained with phospho-specific ATF2-Thr71 antibodies followed by FITC-









Figure 6. Inhibition of JNK, but not p38, abrogates the insulin-induced ATF2 phosphorylation and activation. (A) 
Serum-starved A14 cells were treated with inhibitors as described above prior to stimulation with 10 nM insulin 
(INS) for the indicated times. Cells were fixed and stained with antibodies for Thr69+71-phosphorylated ATF2 
followed by FITC-conjugated secondary antibodies (green). DNA was stained with DAPI (blue). (B) Insulin-
induced ATF2 transcriptional activity was examined in a GAL4-dependent luciferase reporter assay using the 
activation domain of ATF2 fused to the GAL4 DNA binding domain (19). Cells were transiently transfected and 
grown for 8 hours, subsequently serum-starved in DMEM containing 0.5% FBS O/N and treated for 30 minutes 
with vehicle or inhibitors SB203580 or SP600125 before adding insulin (INS; 10 nM). Cells were lysed 16 hrs 
later and luciferase activity was determined. The relative firefly luciferase activity is depicted as the mean 
enhancement of promoter activity in the absence or presence of insulin and/or inhibitors +/- the SD of three 
independent experiments performed in triplicates. Note the different scaling of the left and right y-axis. ** P = 










Figure 7. Time course of nuclear translocation of ERK1/2 and JNK. Serum-starved A14 cells were incubated with 
DMSO, 10 µM U0126 (U) for 15 minutes or 10 µM SP600125 (SP) for 30 minutes prior to stimulation with 10 
nM insulin (INS) for the indicated times. Cells were fixed and stained with antibodies for (A) phosphorylated ERK 
(ERK-PP) or (B) phosphorylated JNK (JNK-PP) and FITC-conjugated secondary antibodies (green). DNA was 












Figure 1. Immunohistochemical staining of mouse liver and pancreas tissue sections with phospho-ATF2-Thr71 
antibodies (ATF2-P71), or hematoxylin (HE; blue) in combination with insulin (brown). Mice were infused with 
either PBS or insulin for the indicated times. Photographs are representative of 2-3 independent animals. 
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